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ABSTRACT 
The marine bryozoan Bugula neritina is the source of the bioactive polyketide 
compounds, the bryostatins.  The biosynthesis of the bryostatins is putatively prescribed by the 
Type I modular polyketide synthase (PKS), bry, from the uncultured bacterial symbiont 
“Candidatus Endobugula sertula”.  The bry gene cluster has a non-canonical, discrete 
acyltransferase (AT) enzymatic domain upstream of the PKS gene cluster.  The AT is 
hypothesized to add the polyketide extender units onto an acyl carrier protein (ACP) in the bry 
PKS and, as such, is termed a trans-AT.  In addition, some trans-ATs have been shown to have 
more extender unit substrate flexibility than cis-ATs, which are usually very substrate-specific.  
The ability of trans-ATs to discriminate between the modular ACPs and load them with the 
v 
 
correct extender unit to form the desired polyketide product during biosynthesis is unclear.  To 
examine how trans-AT’s discriminate between modules, protein-protein interactions between the 
BryP trans-AT and interdomain regions between ketosynthase (KS) and AT regions of PKS 
modules were assessed using surface plasmon resonance (SPR) to compare binding events via 
dissociation data.  On average, BryPAT1 had a higher affinity for BryBM4 KS-AT interdomain 
region as compared to the EryAIII M5 KS-AT interdomain region.  
Bryostatins are versatile compounds that are ecologically relevant for the survival of 
Bugula larvae.  The mechanism for this activity could be due to activation of protein kinase C 
(PKC) via high affinity for the PKC C1b domain.  As the symbiont-produced bryostatins are 
potent activators of a eukaryotic cellular target, the question of how the bryozoan host has 
adapted to their presence arises.  Interestingly, there is variation in symbiont and bryostatin status 
within the genus Bugula, with some species possessing a symbiont that produces bryostatins, 
some species possessing a closely-related symbiont that does not produce bryostatins, and some 
species with no symbiont.  Using SPR, on average, bryostatin has a higher affinity for bryostatin-
producing B. neritina C1b domain as compared to non-bryostatin containing Bugula pacifica and 
Rattus norvegicus C1b domains.  Understanding aspects of bryostatin biosynthesis and symbiont 
effects on the host will provide deeper insight into the vital role that they play in the interaction 
between B. neritina and E. sertula.   
 
INDEX WORDS: Symbiosis, Bryostatins, Protein kinase C, Polyketide synthesis, gene 
expression, natural product-protein interaction 
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1 BACKGROUND 1 
1.1 Natural Products and Symbiosis 2 
Natural products are small molecules that possess biological and/or pharmaceutical 3 
activities produced by organisms ranging from microorganisms to plants to animals (Li & 4 
Vederas, 2009).  Many bioactive products are formed as a result of symbiotic interactions (Piel, 5 
2009), associations between a host and symbiont with a range of outcomes, from mutually 6 
beneficial to parasitic.  These relationships can be obligate or facultative, and have a major 7 
impact on the survival and co-evolution of the partners (Moran, 2006).  In microbial symbiotic 8 
relationships, natural products can be utilized to aid in host development or defense (McFall-9 
Ngai et al., 2013).  For instance, an entomopathogenic nematode has a mutualistic relationship 10 
with the insect pathogen Photorhabdus luminescens that produces the antimicrobial compound 11 
hydroxystilbene, which aids in the growth of juvenile nematodes (Strauch & Ehlers, 1998, Joyce 12 
et al., 2008).  Symbiont-produced bioactive compounds can also play a role in host defenses 13 
against a predator or parasite (Haine, 2008, Lopanik, 2014).  The bacterial symbiont found in the 14 
female rove beetle, Paederus, produces the compound, pederin, which protects eggs and larvae 15 
of the beetle from predatory spiders (Kellner & Dettner, 1996).  Many bioactive symbiont-16 
produced natural products have potential therapeutic applications.  The parasitic fungus Rhizopus 17 
sp. has an endosymbiont, Burkholderia sp. that produces the anti-cancer compound rhizoxin 18 
(McLeod et al., 1996, Partida-Martinez et al., 2007, Schmitt et al., 2008), which causes 19 
antimitotic activity by binding to tubulin (Tsuruo et al., 1986, McLeod et al., 1996, Scherlach et 20 
al., 2006).  The fungal symbiont of the jellyfish Nemopilema nomurai produces four polyketides 21 
with antibacterial activity against pathogenic bacteria, including methicillin-resistant 22 
Staphylococcus aureus 3089 (Liu et al., 2011).  The antitumor compounds mycalamides, 23 
8 
onnamides, and theopederins, similar to pederin, but isolated from different marine sponges, 24 
have the ability to inhibit protein synthesis and cell division (Piel et al., 2004, Witczak et al., 25 
2012).  These examples illustrate the importance of symbiont-produced natural products in 26 
symbiotic relationships, and their bioactivity. 27 
1.2 Bryostatins 28 
Another example of symbiont-produced natural products is the bryostatins (Figure 1.1).  29 
The marine bryozoan Bugula neritina is the source of these 20 polyketide metabolites (Pettit et 30 
al., 1982, Pettit, 1996, Lopanik et al., 2004).  B. neritina harbors the uncultured endosymbiotic γ-31 
proteobacterium, “Candidatus Endobugula sertula” (Haygood & Davidson, 1997), which is 32 
thought to biosynthesize the bryostatins (Davidson et al., 2001, Lopanik et al., 2004, Sudek et 33 
R1 R2
1 A D
2 OH D
3 C D
4 A E
5 A D
6 B C
7 B A
8 C A
9 A A
10 C C
11 A D
12 B H
13 A H
14 C H
15 B OH
16 B H
17 B H
18 B H
19 B C
20 B H
M
O
Figure 1.1 : Structures of bryostatins, with substituent groups at R
1
 and R
2
 indicated in table. 
Bryostatins 3, 19, and 20 feature cyclization indicated with asterisks (*). (Adapted from Davidson 
and Haygood, 1999.) 
9 
al., 2007).  Some bryostatins are unpalatable, and defend B. neritina larvae from predators 34 
(Lindquist, 1996, Lindquist & Hay, 1996, Lopanik et al., 2004).  In eukaryotic cells,  bryostatins 35 
activate protein kinase Cs (PKC) (Wender et al., 1988)are serine-threonine kinases involved cell 36 
signaling cascades of many regulatory processes such cell growth and structure (Newton, 2001, 37 
Newton, 2010).  38 
  39 
1.3 Bugula neritina  40 
The marine bryozoan Bugula neritina is a colonial invertebrate found world-wide in 41 
temperate habitats.  A bryozoan colony is composed of individuals called zooids.  In B. neritina, 42 
embryos are brooded in chambers, termed ovicells, found on the maternal zooid, where they 43 
develop into larvae.  Once developed, the soft bodied, nutrient-rich B. neritina larvae are 44 
released into the water column (Woollacott & Zimmer, 1972) where they are vulnerable to 45 
predation but are protected by the presence of the distasteful bryostatins (Lindquist, 1996, 46 
Lindquist & Hay, 1996, Lopanik et al., 2004).  In larvae, the endosymbiont E. sertula resides 47 
within an indentation on the surface known as the pallial sinus (Woollacott, 1981, Haygood & 48 
Davidson, 1997).  In adult colonies, the symbiont is located in the funicular cords (Woollacott & 49 
Zimmer, 1975, Sharp et al., 2007), which act as a vascular system within the colony, transporting 50 
nutrients and waste (Carle & Ruppert, 1983).  Funicular cords also act as a placental system, 51 
providing nutrients to the growing embryo in the ovicell; it is hypothesized that the symbiont is 52 
transmitted to the next generation larvae through the funicular cords (Woollacott & Zimmer, 53 
1975, Sharp et al., 2007). 54 
Symbiosis is not always characteristic of B. neritina or other Bugula spp.  Both B. 55 
neritina and B. simplex have been shown to possess closely-related, but different species of 56 
bryostatin-producing symbiont (Davidson & Haygood, 1999, Lim & Haygood, 2004), while in 57 
10 
contrast other species (B. stolonifera and B. turrita) lack a symbiont (Woollacott, 1981, Lim-58 
Fong et al., 2008).  In another variation, B. pacifica and B. turbinata are thought to possess a 59 
symbiont but no bryostatins (Lim-Fong et al., 2008).  Furthermore, B. neritina displays 60 
variability in symbiosis with E. sertula with both symbiotic and aposymbiotic colonies of B. 61 
neritina having been identified.  Currently, three sibling species have been identified using B. 62 
neritina mitochondrial cytochrome c oxidase I (COI) sequences: Type D, Type S, and Type N 63 
(Davidson & Haygood, 1999, McGovern & Hellberg, 2003, Fehlauer-Ale et al., 2014).  In the 64 
United States, Type S and Type D have been found in southern California occurring above the 65 
depth of 9 m and a depth below 9 m, respectively, and display differences of 8.1% in a region of 66 
the COI gene.  Interestingly, the symbiont within each host sibling species differ 0.4% their 16S 67 
rRNA genes, and bryostatin composition also varies (Davidson & Haygood, 1999).  The Type D 68 
contains chemotype O bryostatins (bryostatins 1-3), that possess an octa-2, 4-dienoate ester at 69 
C20 of the bryostatin pyran ring (Figure 1).  Bryostatins found in Type S colonies do not contain 70 
the octa-2, 4-dienoate ester, and were designated chemotype M.  Differences in bryostatin 71 
chemotypes are due to the variation in the bry gene cluster expression and composition (Sudek et 72 
al., 2007).  On the Atlantic coast, B. neritina found north of Cape Hatteras have historically been 73 
identified as Type N while colonies found south of the Cape Hatteras and in the Gulf of Mexico 74 
have been characterized as Type S genotype (Davidson & Haygood, 1999, McGovern & 75 
Hellberg, 2003).  Populations north of Cape Hatteras, Type N, have a divergence of 11.5% from 76 
the Type S COI sequences.  Interestingly, this haplotype was found not to possess the symbiont 77 
(McGovern & Hellberg, 2003), or unpalatable bryostatins (Lopanik et al., 2004).  It has been 78 
proposed that less predation pressure at higher latitudes results in reduced defenses in organisms 79 
11 
at higher latitudes (Vermeij, 1978, Bertness et al., 1981, Menge & Lubchenco, 1981), and the 80 
occurrence of undefended, aposymbiotic colonies supported this hypothesis.  81 
More in depth studies of the population structure of host and symbiont have shown that 82 
Type S and Type N can be found on either side of the Cape Hatteras and in some cases present in 83 
the same locations.  Further, colonies of both Type S and N sibling species have been found to be 84 
symbiotic as well as aposymbiotic.  These data indicate that the bryostatins may not be as crucial 85 
for host defense as past research has shown (Linneman et al., 2014).  If the presence of the 86 
symbiont-produced bryostatins is not solely for the purpose of defense, then they may be 87 
required for other functions within the host.   Also not all symbiotic Bugula spp. possess 88 
bryostatins, as in the case of B. pacifica and B. turbinata (Lim-Fong et al., 2008), suggesting that 89 
the relationship is not completely reliant on the bryostatins.  This leads to the question of why do 90 
some species have the bryostatins and others do not.  Also, how do the bryostatins effect the host 91 
when present? It is possible the host has adapted to the presence of symbionts and symbiont-92 
producing bryostatins over time, which has led to a co-evolution event between host and 93 
symbiont.  94 
1.4 Bugula species 95 
Bugula species are a diverse group of bryozoans with varying morphologies, symbionts, 96 
and environments. Bugula species can be found globally in the oceans whether cold or warm 97 
waters (Brock, 2017). Most species are found in fouling habitats and shallow waters; however, 98 
there are bryozoan communities found in deeper regions of the ocean (Davidson & Haygood, 99 
1999, McGovern & Hellberg, 2003, Fehlauer-Ale et al., 2014). While B. neritina has been 100 
widely studied, other Bugula species such as Bugula stolonifera, Bugula pacifica, Bugula turrita, 101 
Bugula turbinata, and Bugula simplex have unique characteristics that are of interest. While B. 102 
12 
neritina colonies have a distinct purple pigmentation, B. stoloniferia and B. turrita are white to 103 
grey in color whereas B. turbinata and B. simplex’s tint can range from brown to yellow colonies 104 
(Hincks, 1886). B. simplex have multi-serial branching, hemispherical ovicells, and long 105 
avicularia only on marginal zooids. B. stolonifera colonies have bi-serial branching with sub-106 
globular ovicells and avicularia. B. turrita has bi-serial, spiral branching with avicularia along 107 
outer lateral of zooid with caduceus ovicells (Ryland, 1960, Ryland, 1991, Ryland et al., 2011). 108 
B. turbinata have multi-serial branching with avicularia. Extracts from B. pacifica, B. turbinata, 109 
B. turrita, B. stolonifera have shown no bryostatin activity while B. neritina and B. simplex have 110 
bryostatin activity (Lim & Haygood, 2004). The contrast between Bugula spp. of symbiont with 111 
bryostatins, symbiont with no bryostatins, and no symbiont, no bryostatin could provide natural 112 
controls for research on the symbiont’s effect on host. 113 
1.5 Bryostatin Biosynthesis 114 
Bryostatins are polyketide molecules that are typically biosynthesized by modular 115 
polyketide synthases (PKS).  Type I PKSs are large modular protein complexes that synthesize 116 
polyketides in a linear assembly-line fashion, with each enzyme being used only once in the 117 
biosynthesis [reviewed in (Fischbach & Walsh, 2006)].  Type I PKSs are organized in modules, 118 
with each module containing multiple catalytic domains responsible for one elongation and 119 
modification of the nascent polyketide.  The enzymatic domains responsible for polyketide 120 
elongation are acyltransferase (AT), acyl carrier protein (ACP), and ketosynthase (KS) while 121 
other enzymatic domains, such as the ketoreductase (KR), dehydratase (DH), enoylreductase 122 
(ER), methyltransferase (MT), and thioesterase (TE) domains, modify the polyketide chain 123 
(Staunton & Weissman, 2001, Fischbach & Walsh, 2006).  During elongation, monomer units, 124 
usually malonyl-CoA or methylmalonyl-CoA, are used to extend the nascent polyketide chain by 125 
13 
two carbons (Haydock et al., 1995, Keatinge-Clay et al., 2003).  For elongation in typical Type I 126 
PKSs, the dedicated AT domain selects a specific extender unit and loads the unit onto its active 127 
site serine.  The AT then transfers the extender unit covalently to the activated ACP. Research to 128 
date suggest that AT domains exhibit a high level of substrate specificity in regard to the 129 
selection of the extender unit, and certain AT amino acid residues are indicative of the substrate 130 
(Haydock et al., 1995, Keatinge-Clay et al., 2003). The KS catalyzes the condensation reaction 131 
of the ACP-bound extender unit to the nascent polyketide chain (Staunton & Weissman, 2001). 132 
 Polyketides such as erythromycin and pikromycin are formed in this general pattern of 133 
elongation.  Erythromycin is a 14-membered macrolide antibiotic (Woodward et al., 1981) 134 
produced by the actinomycete Saccharopolyspora erythraea (McGuire et al., 1952, Cortes et al., 135 
1990, Staunton & Wilkinson, 1997).  The preferred substrate for extender units for all of the AT 136 
domains within the erythromycin PKS (DEBS) is methylmalonyl-CoA (Donadio et al., 1991).  137 
Pikromycin is a14-membered ring macrolide antibiotic produced by another actinomycete, 138 
Streptomyces venezuelae.  The AT domains within the pikromycin PKS cluster (Pik) utilize 139 
malonyl-CoA and methylmalonyl-CoA as extender units in different places (Xue et al., 1998).  140 
1.6 Acyltransferases in Bryostatin Biosynthesis 141 
The bryostatin PKS (bry) is different from canonical Type I modular PKSs as each module 142 
lacks embedded AT domains, and, instead, has AT domains on an ORF upstream of the modular 143 
PKS genes (Sudek et al., 2007).  There are other PKS systems that have discrete AT domains, 144 
such as the leinamycin (Cheng et al., 2003), bacillaene (Butcher et al., 2007), pederin (Piel, 145 
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2002), onnamide (Piel et al., 2004), and mupirocin (El-Sayed et al., 2003) biosynthetic gene 146 
clusters.  LmnG, a discrete AT from the leinamycin gene cluster, was shown to load extender 147 
units onto ACPs and an incomplete module in vitro (Cheng et al., 2003).  In bry, the two AT 148 
domains, BryPAT1 and BryPAT2, are not embedded within the modules, but instead are located 149 
upstream of the modular PKS genes in a single ORF called BryP.  The discrete nature of the AT 150 
domains suggests a trans mode of action, in which one AT, BryP, loads extender units on each 151 
modular ACP within the PKS (Sudek et al., 2007) (Figure 1.2).   152 
Phylogenetic analysis indicated that BryPAT1 is closely related to other trans-ATs that 153 
utilize malonyl-CoA as a substrate, and in vitro biochemical analysis demonstrated that it loaded 154 
malonyl-CoA onto variety of excised ACPs  (Lopanik et al., 2008).  BryP AT1 loaded both 155 
B
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Figure 1.2:  Domain architecture of Bry, Ery, and Pik PKS modules with native substrates.  
 (A) trans-AT BryBM4 with malonyl-CoA, (B) cis-AT Ery AIII M6 with methylmalonyl-CoA, and 
(C) cis-AT PikAIV M6 with methylmalonyl-CoA. 
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malonyl- and methylmalonyl-CoA onto two excised ACPs from the bry gene cluster (BryB M7 156 
ACP and BryB M3 ACP), although it prefers malonyl-CoA.  Bryostatins have two geminal 157 
dimethyl groups (C8 and C18, Figure 1.1) that are hypothesized to be produced by modules with 158 
methyltransferase (MT) domains (BryBM4 and BryCM9) (Sudek et al., 2007).  These modules 159 
could utilize either methylmalonyl-CoA or malonyl-CoA, and the MT would methylate the 160 
nascent polyketide chain either once (with methylmalonyl-CoA) or twice (with malonyl-CoA).  161 
As previously mentioned, the erythromycin gene cluster (Ery) has cis-ATs with a native 162 
substrate of methylmalonyl-CoA for all modules, while pikromycin (Pik) cis-AT native 163 
substrates are methylmalonyl-CoA (for modules 1-4, 6), and malonyl-CoA (module 5) (Figure 164 
A B
Figure 1.3: PKS module loading using [14C] malonyl-CoA and [14C] methylmalonyl-CoA.  
 (A) BryPAT1 is able to transfer malonyl-CoA onto EryAIII M6 ATº and holo BryB M4.  (B) BryPAT1 is 
unable to transfer malonyl-CoA or methylmalonyl-CoA on PikAIV M6 ATº (null-AT).  PikAIV M6 wild-type 
(wt) is able to self-load native methylmalonyl-CoA.   From (Lopanik, et al., 2008). 
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1.2).  Further experiments with overexpressed complete modules demonstrated that BryP AT1 165 
was able to complement the EryAIII M6 ATo mutant by loading malonyl-CoA (the unnatural 166 
substrate) onto the cognate ACP (Figure 1.3A).  Interestingly, BryP AT1 was unable to load 167 
malonyl-CoA onto the AT-null mutant module 6 of the pikromycin gene cluster (Figure 1.3B); 168 
the PikAIV M6 also utilizes methylmalonyl-CoA as its native substrate.  The inability of BryP 169 
AT1 to load a substrate onto PikAIV M6 AT
o despite the similarity of the domain composition of 170 
both modules (EryAIII M6: KS, AT, KR, ACP, TE, and PikAIV M6: KS, AT, ACP, TE) and 171 
native AT substrates (methylmalonyl-CoA), indicates a possible recognition system by which the 172 
trans-AT can discriminate between the modules.    173 
1.7 Host Adaptation to Natural Products 174 
Microbes are a prolific source of bioactive natural products, many of which have been 175 
developed into pharmaceuticals (Li & Vederas, 2009).  Microbes that are in mutualistic 176 
relationships with eukaryotic hosts can also produce bioactive compounds. In some cases, these 177 
compounds can play a role in the defense of the host (Moran, 2006).  For example, pederin is a 178 
symbiont-produced compound that allows rove beetle larvae to gain protection for predatory 179 
wolf spiders (Piel, 2002). Enterococcus faecalis has been shown to its protect host, 180 
Caenorhabditis elegans, from other bacterial pathogens such as Staphylococcus aureus by 181 
increasing antimicrobial superoxide production (King et al., 2016).  Actinobacteria strains found 182 
in insects like bees and wasps may produce secondary metabolites that confer protection against 183 
natural predators (Abt et al., 2012).  However, most of the time, the symbiont’s role in the 184 
relationship with the host has not been elucidated.  While there are several examples to illustrate 185 
the external effects that symbiont produced compounds can have on the host, internal effects 186 
may be much harder to confirm.  The close association of host and symbiont, by nature, means 187 
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that symbiont-produced bioactive compounds may interact with eukaryotic host cellular targets 188 
to elicit change in the host. The extent of host adaptation to the presence of these compounds is 189 
not well understood for most relationships.  One exception is the relationship between the plant-190 
pathogenic fungus Rhizopus microsporus and its bacterial symbiont, Burkholderia rhizoxinica 191 
(Partida-Martinez & Hertweck, 2005).  Fungal strains that contain the rhizoxin-producing 192 
symbiont possess a mutation in their β-tubulin gene.  The mutation allows for a decreased 193 
affinity to rhizoxin, an otherwise toxic compound (Schmitt et al., 2008).  This relationship 194 
demonstrates significant co-evolution between host and symbiont; it is also possible that host and 195 
symbiont coevolve such that these compounds can become important for normal host 196 
physiology.  197 
1.8 Protein Kinase C and Bryostatin 198 
Protein kinase C (PKC) is a serine-threonine kinase involved in transducing cellular signals 199 
(Newton, 1995, Newton, 2001).  PKCs are important in fundamental processes such as cell 200 
Figure 1.4: Architecture of PKC isoform domains.  
cPKC = conventional, nPKC = novel PKC, and αPKC = αtypical PKC.  PS = 
phosphatidyl serine, DAG = diacyl glycerol. (Adapted from Newton, 2001 and Rosse, 
et al., 2010)  
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growth, changes in cell pH levels, and cytoskeleton structure alterations (Newton, 1995, Griner 201 
& Kazanietz, 2007).  When PKCs are inactive, they are found in the cytosol of the cell (Newton, 202 
2001); upon activation, PKCs travel to the cell membrane for cell signaling and are eventually 203 
degraded by proteases(Newton, 1995).  There are three types of PKCs isoforms: conventional 204 
(cPKC, α, βI, βII, γ), novel (nPKC, δ, ε, η, θ), and atypical (aPKC, ξ, λ, ι) (Figure 1.4).  205 
All three isoforms possess a catalytic domain, but differ in their regulatory domains 206 
(Newton, 2001, Newton, 2010).  The cPKCs have C1a and C1b Zn-finger domains that bind 207 
DAG, a pseudosubstrate domain, and a calcium binding domain.  The nPKCs differ by not 208 
having a calcium binding region.  The aPKCs lack the calcium binding domain and the C1b 209 
region of the DAG-binding domain (Newton, 2001). 210 
Bryostatin binds with high affinity to the C1b domains in cPKCs and nPKCs (Kraft et al., 211 
1986, De Vries et al., 1988, Kraft et al., 1988).  Bryostatin 1 has been shown to induce rapid 212 
Figure 1.5: Translocation of PKCβ1-GFP by 200 nM bryostatin 1 in transiently transfected 
CHO-k1 cells. 
 (A) predose, (B) 5 min postdose, and (C) 38 min postdose (D–F) translocation of PKCδ-GFP 
by 200 nM bryostatin 1, same time points (Wender, et al., 2011) 
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translocation in δPKC and βPKC to the cell membrane in transfected CHO cells whereas 213 
bryostatin 2, differing by a C7 acetate group, has no effect (Figure 1.5).  Conventional αPKC 214 
was also activated but to a lesser degree.  Furthermore, bryostatin 1 had a higher level of PKCα 215 
degradation after prolonged activation as compared to PKCδ and PKCβ (Wender et al., 2011).  216 
Differing activation levels and selectivity of the bryostatins among PKC isoforms suggests that 217 
these compounds could regulate PKC. 218 
1.9 Bryostatin effects on B. neritina PKCs 219 
Microbial endosymbionts are often the source of bioactive natural products, and in order to 220 
fully understand host/symbiont coevolution, it is necessary to understand the effects of these 221 
compounds on the host.  It is reasonable to propose that, due to the close association between B. 222 
neritina and E. sertula, and the high affinity of the bryostatins for eukaryotic PKCs, the presence 223 
of the bryostatins has influenced the evolution of the host PKCs.  In B. neritina, extended 224 
exposure to bioactive bryostatin metabolites has likely led to host adaptation to the symbiont 225 
and/or symbiont metabolites (Mathew et al., 2016).  Over time, the host could adapt to the 226 
presence of the symbiont-produced bryostatins such that they are have become necessary for host 227 
physiology. 228 
In order to identify potential effects of the symbiont on the host, the symbiont was cured 229 
from B. neritina using an antibiotic treatment to observe colonies without the symbiont.  Colony 230 
growth was similar in control and cured colonies, indicating that the presences of the symbiont 231 
and bryostatins had no significant effect on growth.  Interestingly, significantly fewer 232 
reproductive structures, ovicells, were observed in B. neritina symbiont-reduced colonies 233 
(Mathew et al., 2016).  This suggests that either the symbiont or the symbiont-produced 234 
bryostatins may be involved in the physiological process of reproduction.  In addition, Western 235 
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blot analysis of bryostatin-activated cPKCs in symbiotic colonies exhibited lower molecular 236 
weight proteins in total protein extracts (Mathew et al., 2016).  Crude protein extracts from 237 
antibiotic treated B. neritina colonies, however, did not have the same lower molecular weight 238 
banding pattern.  Similar results were also seen in protein extracts of additional naturally 239 
symbiotic and aposymbiotic colonies (Mathew et al., 2016) .These results indicate that PKCs in 240 
B. neritina are potentially affected by the presence of bryostatins.  As previously mentioned, 241 
bryozoans in the genus Bugula vary in their symbiotic state, with some species being 242 
aposymbiotic, and some host species possess a symbiont closely-related to E. sertula that does 243 
not produce bryostatins (Lim-Fong et al., 2008).  These varying species present natural controls 244 
to test the hypothesis that the host PKC has evolved in the presence symbiont-produced natural 245 
products.  246 
1.10 Research Aims  247 
The in vitro protein-protein interactions between heterologously expressed BryPAT1 and 248 
KS-AT interdomain regions of BryB M4, EryAIII M6, and Pik AIV M6 is one goal of this 249 
research.  Binding affinities of possible protein interactions will be determined using surface 250 
plasmon resonance.  Further work to elicit information about specific amino acids involved in 251 
the proteins ability to bind the trans-AT will be studied by amino acid substitutions using site-252 
directed mutagenesis.  Changes in the amino acid sequences could change the ability of BryPAT1 253 
to bind.  254 
Understanding how bryostatin biosynthesis occurs is important; nonetheless, identifying 255 
affects bryostatins could have on the host is also vital.  Since bryostatins have the ability to 256 
activate PKCs, another goal of research will focus on identifying PKC C1b domain in B. neritina 257 
and Bugula spp.  Once C1b domains are detected, each sequence will be cloned into a vector for 258 
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protein expression.  The C1b domain constructs from the multiple species will be tested against 259 
bryostatin-1 using SPR to determine binding affinities and possibly pinpoint amino acid residues 260 
involved in the PKC activation.  261 
 262 
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2 MODULE RECOGNITION BY DISCRETE ACYLTRANSFERASE (AT) IN 282 
BRYOSTATIN BIOSYNTHESIS     283 
 284 
2.1 Introduction  285 
Polyketide synthases are large, multi-modular proteins that catalyze the biosynthesis of 286 
polyketide molecules (Keatinge-Clay, 2012). The nascent polyketide chain is covalently attached 287 
to the PKS, and is essentially “passed along” the enzyme as it is grown and modified.  Often, the 288 
PKS modules are divided on different ORFs, such that the growing polyketide chain will have to 289 
be transferred from a module on one ORF to a module on the next ORF.  Because of this, 290 
protein-protein recognition is important for many aspects of polyketide biosynthesis such as 291 
module to module interaction, delivery of the substrate to the ACP, and in catalytic steps 292 
involving the KS domains [reviewed in (Xu et al., 2013)].  In PKS gene clusters with trans-AT 293 
domains, the free-standing AT must be able to load the extender unit onto the cis-ACP domain.  294 
Further, some PKSs have more than one trans-AT domain, with different extender unit substrate 295 
preferences, which must load the correct cis-ACP domain with the correct extender unit (Musiol 296 
et al., 2011).  This indicates that trans-AT domains have the ability to recognize their cognate 297 
embedded ACP domains.  The trans-AT has been identified in several natural product-bacterial 298 
systems from exotic prokaryotes to pathogenic bacteria as well as those involved in biocontrol 299 
(Piel, 2010).  Pederin (Piel, 2002), kirromycin (Weber et al., 2008), Rhizoxins (Partida Martinez 300 
& Hertweck, 2005, Loper et al., 2008) are all bacterial natural products synthesized by PKS 301 
systems with trans-ATs. 302 
Previous data suggest that the trans-AT BryP AT1 can discriminate between modules, as 303 
it was able to load malonyl-CoA onto BryB M4 and EryAIII M6, but not on PikAIV M6 304 
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(Lopanik et al. 2008).  One mechanism that may account for this differential activity is protein-305 
protein recognition of the KS-AT interdomain regions.  In order to test the hypothesis that KS-306 
AT interdomain regions are important for trans-AT recognition, sequences of BryPAT1 and the 307 
Ery, Pik, and Bry KS-AT interdomain regions were identified, cloned into an expression vector, 308 
and overexpressed. Overexpressed proteins were purified and concentrated to allow for in vitro 309 
protein-protein interactions quantification using surface plasmon resonance (SPR).  In SPR, an 310 
optical biosensor detects changes in the binding of an immobilized molecule with an analyte 311 
molecule in real-time without labeling (Malmqvist, 1999).  Changes in light reflection in 312 
response to a binding event plotted against time provides information about molecule 313 
interactions and compound affinities.  A range of SPR experiments can be achieved using chips 314 
that can consist of a gold side for electron excitation and another side that can be composed of 315 
various dextran matrixes to immobilize molecules. Each dextran matrix is geared toward a 316 
specific molecule immobilization and experiment (Englebienne et al., 2003, Zeng et al., 2014).   317 
For example, histidine-tagged proteins can be attached to a nitrilotriacetic acid (NTA) dextran 318 
sensor chip via nickel II solution which can be regenerated (Kimple et al., 2010).  CM5 sensor 319 
chips have a carboxymethylated dextran that irreversibly immobilize molecules via -NH2, -SH, -320 
CHO, -OH, or -COOH groups (Drescher et al., 2009).  In this study, levels of interaction will be 321 
based upon binding affinities of the BryPAT1 to the KS-AT interdomain regions of BryB M4, 322 
EryAIII M6, and PikAIV M6. I hypothesize that the binding affinities for BryPAT1 to BryB M4 323 
KS-AT and EryAIII M6 KS-AT will be higher than in Pik AIV M6 KS-AT.  Binding affinities of 324 
BryPAT1 with the KS-AT interdomain regions will confirm if the trans-AT can recognize and 325 
interact within these regions of the module for extending nascent polyketide chains. 326 
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2.2 Materials and Methods 327 
2.2.1 Cloning of KS-AT interdomain regions in BryBM4 and PikAIVM6 328 
2.2.1.1 KS-AT interdomain region identification and primer design 329 
The KS-AT interdomain regions of BryB M4 (ABM63527), PikAIV M6 (AF079138), 330 
and EryAIII M6 (Q03133) modules were located by identifying the KS and AT domains using 331 
MotifScan.  Amino acid alignments of other AT-less PKS systems (Tang et al., 2004) were used 332 
to identify conserved amino acid residues to determine the 3’ end of the KS-AT regions in BryB 333 
M4, as the lack of AT domain made the C-terminus more difficult to identify.  GOR software 334 
(Garnier et al., 1996) was used to identify ordered regions (i.e., α-helix, β-sheet), and constructs 335 
were designed so that the N- and C-termini occurred on a non-ordered, extended region.  Primers 336 
were designed to flank the KS-AT interdomain regions in extender regions as to not disrupt areas 337 
of α helices or β sheets. 338 
2.2.1.2 PCR of KS-AT interdomain regions 339 
Multiple primer sets (Table 2.1) were designed to amplify KS-AT interdomain regions 340 
for BryBM4, Ery AIII M6, and PikAIV M6. The KS-AT interdomain region of BryBM4 was 341 
PCR amplified using Phusion High-Fidelity DNA polymerases (Thermo Scientific, Pittsburgh, 342 
PA, USA) protocol. PCR reactions were carried out by initial denature at 98°C for 30 s, with 35 343 
cycles of denatured at 98°C for 10 s, annealed for 30 s (temperature varied per primer set), and 344 
elongated at 72°C for 25 s, and final extension of 72°C for 5 min. PCR amplicons were separated 345 
using gel electrophoresis. PCR amplicons of the correct size were then purified using GeneJET 346 
PCR purification kit (Thermo Scientific, Vilnius, Lithuania).  347 
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Table 2.1 Primers used in KS-AT Cloning 349 
 350 
2.2.1.3 Synthetic PikAIV M6 Construction 351 
After several unsuccessful attempts to amplify and clone the PikAIV M6 KS-AT region, 352 
the KS-AT interdomain region was synthetically constructed using gBlocks® Gene Fragments 353 
(IDT, Coralville, IA, USA).  The theoretical sequence was manually codon optimized with 354 
inserted restriction digest sites for SacI and a stop codon just before a XhoI site.  SacI and XhoI 355 
(NEB, Ipswich, MA, USA) were used to digest synthetic PikAIV M6 KS-AT region for 2 hours 356 
at 37°C.  The digested gene fragment was then visualized using gel electrophoresis to ensure 357 
proper DNA size. The DNA band was purified using GeneJET gel extraction kit (Thermo 358 
Scientific, Vilnius, Lithuania) and ligated into a SacI and XhoI digested pCDF-1b vector 359 
(Novagen) containing an N-terminal 6x Histidine tag using T4 Ligase (NEB, Ipswich, MA, 360 
USA) for 4 hours at 16°C. The ligated products were transformed into E. coli XL1-Blue 361 
(Stratagene) chemically competent cells (E. coli Transformation Buffer set, Zymo Research 362 
Name Sequence (5’→3’) Target 
Product 
size (bp) 
Annealing 
Temperature 
Purpose 
BryKS-AT F TGAGTCGAATTCAAATGTTATCAGTAGAT BryBM4         
KS-AT 
Region 
978 47°C PCR 
BryKS-AT R ATAAAACTCGAGCGCTAGTCCATTGCCTCGG 
EryKS-AT F CCTGGTGAATTCFATGCTCTGCCG Ery AIII 
M6           
KS-AT 
Region 
490 64°C PCR 
EryKS-AT R ACCCTGCTCGAGGAATCAGAAAAC 
PikKS-AT F1 CTGCCGAGCTCGAAGACCCTGCACGT 
PikM6                     
KS-AT 
Region 
482                                         
691                                          
823 
60°C                   
60°C               
60°C 
PCR 
PikKS-AT F2 GAGCGACGAGCTCGTGGACGTCGTGG 
PikKS-AT F3 CACCGGAGCTCGGTCCTGGCCGTCGT 
PikKS-AT R1 GCCGGGCYCGAGGAATCAGAACGCCA 
T7 TAATACGACTCACTATAGGG T7 
Promoter 
Region 
343 
(+insert) 
54°C PCR 
T7 Terminus GCTAGTTATTGCTCAGCGG 
26 
Corp., Irvine, CA, USA), plated on Luria Bertani- Miller agar (LB) (BD, Sparks, Maryland, 363 
USA) with 50 µg/mL kanamycin (KAN), and incubated at 37°C overnight. Resulting colonies 364 
were screened for insert by colony PCR using T7 and T7 terminus primers (Table 2.1) and One 365 
Taq Polymerase (NEB, Ipswich, MA, USA). PCR reactions were carried out by initial denature 366 
at 94°C for 5 minutes, with 35 cycles of denatured at 94°C for 30 sec, annealed for 30 sec at 367 
54°C, and elongated at 68°C for 50 sec, and final extension of 68°C for 5 min. Colony PCR 368 
amplicons of pCDF-1b::PikAIV KS-AT with the size of interest were extracted using Zyppy™ 369 
Plasmid Miniprep Kit (Zymo Research Corp., Irvine, CA, USA).   370 
2.2.1.4 Construction of Recombinant Plasmids 371 
EA011 was previously constructed by ligating a PCR amplicon [generated with Phusion 372 
Taq (NEB, Ipswich, MA, USA)] into the pET28 vector via EcoRI and XhoI digest sites. The 373 
BryBM4 PCR amplicons were digested with EcoRI and XhoI  for 2 hours at 37°C and visualized 374 
using gel electrophoresis to ensure proper DNA size.  Digest DNA band was excised and 375 
purified using GeneJET gel extraction kit (Thermo Scientific, Vilnius, Lithuania).  BryBM4 376 
purified, digested product was then ligated into a purified EcoRI and XhoI digested pET28b 377 
vector (Novagen) containing an N-terminal 6x Histidine tag using T4 Ligase (NEB, Ipswich, 378 
MA, USA) for 4 hours at 16°C. The ligated products of BryB M4 and Ery AIII M6 were 379 
transformed into chemically competent E. coli XL1-Blue (Stratagene) chemically competent 380 
cells, plated on LB agar with 50 µg/mL kanamycin (KAN), and incubated at 37°C overnight. 381 
Resulting colonies were screened for insert by colony PCR using T7 and T7 terminus primers 382 
(Table 2.1) and One Taq Polymerase (NEB, Ipswich, MA, USA). PCR reactions were carried out 383 
by initial denature at 94°C for 5 min, with 35 cycles of denatured at 94°C for 30 s, annealed at 384 
54°C for 30 s, and elongated at 68°C for 50s, and final extension of 68°C for 5 min. Colony PCR 385 
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amplicons of pET28b::BryBM4 KS-AT were visualized using gel electrophoresis and bands with 386 
the size of interest were extracted using Zyppy™ Plasmid Miniprep Kit (Zymo Research Corp., 387 
Irvine, CA, USA) and quantified using Nandrop. 388 
After plasmid purification, the insert was sequenced using the T7 and T7 terminator 389 
primers at the DNA Analysis Facility at Yale University (New Haven, CT, USA). Consensus 390 
sequences were aligned to theoretical construct sequences for confirmation using MegAlign 391 
(Lasergene) software.  Colonies with the correct insert were named Ery AIII M6 (EA011), 392 
BryBM4 KS-AT (pKB114), and PikAIV M6 (pKB027). 393 
2.2.2 Protein Overexpression of KS-AT Recombinant Constructs 394 
2.2.2.1  Cell Growth and Induction 395 
BryPAT1 (pNL020), BryBM4 KS-AT (pKB114), Ery AIII M6 (pEF011), and PikAIV 396 
M6 (pKB027) plasmids were transformed into chemically competent Escherichia coli Rosetta 397 
Blue (Novagen) cells that contain rare codons that help with expression of proteins. Plasmids 398 
were initially grown in 50 mL tubes with 10 mL of Luria Bertani- Miller broth (LB) with 50 399 
µg/mL kanamycin (KAN), 34 µg/mL chloramphenicol (CAM), and 12.5 µg/ mL tetracycline 400 
(TET) overnight at 37°C shaking at 250 rpm. A second pass of the cells were grown in 2 liter 401 
flasks with 1.5 liters of terrific broth (TB) (Harbor, 2015) with 5% glycerol, 50 µg/mL KAN, 34 402 
µg/mL CAM, and 12.5 µg/ mL TET at 25°C shaking at 200 rpm. Cell densities were measured 403 
every hour using a spectrophotometer (Eppendorf, Hamburg, Germany) until cells reached 404 
optical density (OD600) of 1.  Flasks were then incubated at 16°C for 1 hour to acclimate cells to 405 
lower temperature. Rosetta Blue cells were induced with 100 mM IPTG and incubated with 406 
shaking at 200 rpm at 16°C for 24 hours. 407 
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2.2.2.2 Extraction of Recombinant KS-AT proteins 408 
Cells were centrifugated at 4,000 rpm at 4 °C for 25 minutes in 750 mL sterile containers 409 
and the supernatant was discarded. The protein was extracted from the cell pellet using 410 
BugBuster® (Merck Millipore, Darmstadt, Germany) reagent specifications. BugBuster® was 411 
diluted 1:10 with QIAexpressionist (Qiagen, Valencia, California, USA) lysis buffer pH 8 412 
consisting of 50 mM sodium phosphate (monobasic), 300 mM sodium chloride, and 10 mM 413 
imidazole. Cells were resuspended in the 1X Bugbuster® and incubated with slight agitation for 414 
1 hour at room temperature. The soluble and insoluble protein fractions were separated by 415 
centrifugation at 4,000 rpm for 40 minutes. After centrifugation, the supernatant was collected as 416 
the soluble protein while the pellet was resuspended in 1X Bugbuster® as the insoluble fraction. 417 
All protein fractions were stored at -80 °C.  418 
2.2.3 Purification of Recombinant KS-AT constructs 419 
2.2.3.1 Ni-NTA purification 420 
The target proteins were purified from the total soluble protein fraction with Ni-NTA 421 
chromatography. Ni-NTA chromatography was performed by incubating the soluble fraction 422 
with Ni-NTA agarose (Qiagen, Hilden, Germany) according to protocol specification of 10 µL 423 
resin to 50-100 µg of protein (Qiagen, 2003). The protein - Ni-NTA agarose suspension was 424 
incubated at 4°C with slight agitation for 1 hour. Protein samples were transferred to a column 425 
where cell lysate was removed by gravity flow leaving only the agarose matrix and attached 426 
proteins.  The column was washed twice with wash buffer pH 8 consisting of 50 mM sodium 427 
phosphate, 300 mM sodium chloride, and 20 mM imidazole.  His-tag purified proteins were 428 
eluted from the columns using elution buffer pH 8 consisting of 50 mM sodium phosphate, 300 429 
mM sodium chloride, and 250 mM imidazole. Protein fractions were separated using SDS-430 
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PAGE. SDS-Page was performed using 4-20% Mini-PROTEAN® TGX™ (Bio-Rad, Hercules, 431 
California, USA) precast gels and a 10-250 kDa protein ladder (NEB, Ipswich, MA, USA) to 432 
visualize protein bands.  433 
 434 
2.2.3.2  Thrombin Cleavage of 6X His-tag from BryAT1 435 
BryPAT1 (pNL020) was concentrated using Amicon® Ultra-4 centrifugal filters (Merck 436 
Millipore Ltd., Tullagreen, Cork, Ireland) for 30 minutes at 4,000 rpm at 4°C. pNL020 was 437 
exchanged into calcium chloride buffer consisting of 50 mM Tris-HCl, pH 8, and 10 mM 438 
calcium chloride by centrifuging at 4,000 rpm for 30 minutes at 4°C in Amicon® Ultra-4 filter. 439 
Thrombin cleavage was performed according Thrombin CleanCleave™ Kit (Sigma-Aldrich, St. 440 
Louis, Missouri, USA) protocol. His-tagged proteins were suspended in cleavage resin at room 441 
temperature with gentle agitation for 4 hours. pNL020 was recovered by supernatant collection 442 
using room temperature centrifugation at 2,500 rpm for 5 minutes.  443 
 444 
2.2.3.3 Size-Exclusion Chromatography 445 
pNL020, pKB114, and pEF011 were further purified with size-exclusion chromatography 446 
(SEC) using a fractionation range of 3000–70000 Da. The column was packed using 15 mL of 447 
Superdex® 75 agarose beads (Sigma-Aldrich, St. Louis, Missouri, USA) in a XK16/20 (GE, 448 
Uppsala, Sweden) glass column. SEC purification running buffer consisted of 0.2µm filtered 449 
50mM monobasic sodium phosphate, 50mM dibasic sodium phosphate, and 150mM sodium 450 
chloride. Purification was performed on an ÄKTA Explorer 100 (GE Healthcare, Malbourgh, 451 
MA, USA) at 0.4 mL/min flow rate for approximately 1 hour. All protein fraction volumes 452 
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collected were 2 - 4 mL.  Each fraction was visualized using SDS-Page to locate the protein size 453 
of interest. 454 
2.2.3.4  Protein Concentration and Quantification 455 
Protein fractions with the band of interest were concentrated using Amicon® Ultra-4 456 
centrifugal filters for 30 minutes at 4,000 rpm at 4°C. Buffer exchange was performed using 457 
HBS-P buffer consisting of 10mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 458 
pH 7.4, 150mM sodium chloride, 0.05% Tween 20, and 0.1% DMSO by centrifugation for 40 459 
minutes at 4,000 rpm at 4°C. Concentrated proteins were then filtered with 0.22 µm low protein 460 
binding Durapore® (PVDF) membrane (Merck Millipore Ltd., Tullagreen, Cork, Ireland). 461 
Protein concentrations were quantified by Pierce™ bicinchoninic acid (BCA) assay (Pierce 462 
Biotechnology, Rockford, Illinois, USA) using bovine serum albumin (BSA) as a standard. The 463 
protein concentrations were measured using a Wallac-Victor2 plater reader (Perkin Elmer, 464 
Bradford, Connecticut, USA) at 600nm.  465 
2.2.4 Protein-Protein Interactions of Recombinant Constructs 466 
2.2.4.1 Surface Plasmon Resonance  467 
The protein-protein interactions were assessed with surface plasmon resonance (SPR) to 468 
quantify the binding affinities of BryPAT1 to the different polyketide KS-AT interdomain 469 
regions. SPR experiments were performed with BryBM4 and EryAIII M6 KS-AT affixed to 470 
Series S Sensor Chip NTA (GE Healthcare) via the 6x-His tag. The NTA sensor chip consists of 471 
a gold metal film on one side, and the other side is a dextran matrix to which the 6x-His tag 472 
ligand is bound using a nickel chloride solution.  The gold metal film is exposed to a polarized 473 
light source causing the excitation of electrons on the gold metal surface, resulting in surface 474 
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plasmons.  The KS-AT proteins, ligands, are tethered to the chip and were exposed to the 475 
analyte, BryP AT1, as the buffer solution flows across the chip.  As the analyte binds to the 476 
ligand, the light refraction on the sensor chip changes causing angles of resonance shown as 477 
response units (RU).  Angles of resonance due to light refraction are measured and analyzed 478 
according to association (ka), binding of the analyte to the sensor chip ligand, and disassociations 479 
(kd), and removal of bound analyte from ligand.  Data are provided in a sensorgram consisting of 480 
plotted data points of RU versus time (seconds).  Binding affinity of the analyte and ligand is 481 
provided in ability of the analyte to be disassociated (kd) from the ligand.  The affinity constant 482 
KD is calculated by the ratio of rate constants ka and kd (KD = kd / ka). The Kd was measured at 483 
five different analyte concentrations ranging between 0.1 and 10 times the Kd of the interaction.   484 
Surface plasmon resonance was performed on a Biacore T-200 (GE Healthcare, Uppsala, 485 
Sweden) instrument using a Series S Sensor Chip NTA (Lot # 10250946, GE Healthcare, 486 
Uppsala, Sweden). The experimental running buffer consisted of 0.01 M 4-(2-hydroxyethyl)-1-487 
piperazineethanesulfonic acid (HEPES) pH 7.4, 0.15 M sodium chloride (NaCl), and 0.005% 488 
Tween 20.  Purified proteins derived from  pKB114 (41 μg) and pEA011 (54 µg) were bound to 489 
the NTA sensor chip via 6X His-tag using a 0.5 mM nickel chloride solution (NTA Reagent Kit, 490 
GE Healthcare, Uppsala, Sweden).  Proteins were then cross-linked captured onto the NTA chip 491 
using 20 μM N-hydroxysuccinimide (NHS) / 5 μM 1-ethyl-3-(3-dimethylaminopropyl) 492 
carbodiimide (EDC) (Amine Coupling Kit, GE Healthcare, Uppsala, Sweden) for 7 min at flow 493 
rate of 5 μl/min and excess crosslinkers were quenched by injection of 1 M ethanolamine for 494 
10 min. Any remaining nickel chloride solution was removed using 0.35 M 495 
ethylenediaminetetraacetic acid (EDTA) (NTA Reagent Kit, GE Healthcare, Uppsala, Sweden). 496 
Single cycle kinetics were measured at 10 hertz (Hz) with a 30 µL/min flow rate for a 60 second 497 
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association time and a 600 second dissociation time at 25°C. pNL020 was diluted in HBS-P to 498 
achieve experimental analyte concentrations of 0 µM, 0.117 µM, 0.234 µM, 0.467 µM, 0.935 499 
µM, 1.837 µM, 3.75 µM, and 7.5 µM. The NTA chip was regenerated using 0.35 M 500 
ethylenediaminetetraacetic acid (EDTA) (NTA Reagent Kit, GE Healthcare, Uppsala, Sweden). 501 
Response units and time were evaluated using Biacore T200 Software v3.1 with parameters of 4 502 
seconds before injection stop and 5 seconds after with a steady state curve fit. Channel one and 503 
Channel 3 of NTA chip were used as a reference blanks to subtract background to achieve a 504 
baseline for accurate KD calculations. 505 
2.3 Results 506 
2.3.1.1 KS-AT Construct Sequences and Overexpression Confirmation 507 
KS and AT regions of BryB M4, Ery AIII M6, and PikAIV M6 were located using 508 
MotifScan. Regions between the KS and AT regions were recorded and aligned to identify 509 
differences in amino acid sequences (Figure 2.1). BryB M5, Ery AIII M5, and Pik AIII M5 510 
modules were added into the alignment to give more strength to the alignment of conserved 511 
Figure 2.1 Alignment of Bry, Ery, and Pik modules of KS-AT interdomain regions 
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regions. The differences seen in the amino acid sequence could be used to explain the ability of 512 
Bry and Ery modules to accept the BryAT1.  Similarities between Bry and Ery are seen at 513 
positions 6, 48, and 55 while Pik differs in these areas. One of these amino acid locations could 514 
potentially be the difference in the ability of the AT to load an extender unit onto the Bry and 515 
Ery modules and not the Pik.   516 
Previously cloned, BryPAT1 (pNL020) and Ery AIII M6 (pEA021) constructs were easily 517 
transformed and expressed in the Rosetta Blue cells with the protein of interest found in the 518 
soluble fraction (Figure 2.1).  BryPAT1 (pNL020) has a protein size of approximately 32.3 kDa 519 
while Ery AIII M6 (pEA021) has a size of about 21.2 kDa. The empty pET28b vector was used 520 
as a negative control to confirm overexpression in constructs. The PikAIV M6 KS-AT primers 521 
Figure 2.2: SDS-Page of KS-AT Interdomain Region Constructs 
Overexpressed soluble (S) and Ni-NTA (His-tag) purified proteins of EryAIII M6 KS-
AT (pEA021, ~21.2kDa), BryBM4 KS-AT (pKB114, ~34.6 kDa), and BryAT1 
(pNL020, ~32.3 kDa) with NEB (10-250 kDa) protein ladder.  pET28b lane is the 
empty vector. 
 
pEA021 
34 
were effective in amplifying the KS-AT interdomain region using PCR. However, the Pik 522 
amplicon was unable to be cloned successfully cloned into the pET28b vector. After several 523 
attempts, the PikAIV M6 KS-AT plasmid was not able to be successfully transformed into XL1-524 
Blue cells. In an effort to continue with the Pik construct, the PikAIV M6 KS-AT sequence was 525 
codon optimized and synthetically constructed by gBlocks® Gene Fragments. The synthetic 526 
PikAIV M6 KS-AT sequence was successfully cloned into the pCDF-1b vector. The pCDF-527 
1b:PikAIV M6 KS-AT (pKB027) construct was transformed into both XL1-Blue and Rosetta 528 
Blue cell lines, although it failed to produce any protein of interest in the soluble fraction after 529 
multiple attempts. BryBM4 KS-AT (pKB114) (Figure 2.2) was cloned into the pET28b vector 530 
and expressed in the Rosetta Blue cells. pKB114 has a size of about 34.6 kDa which is slightly 531 
larger than pEA021 construct due to the primer combination design. pKB114 consists of a small 532 
region of KS domain as well as the KS-AT interdomain in the construct whereas pEF011 533 
consists of just the KS-AT interdomain region. 534 
2.3.1.2 KS-AT Construct Purified Proteins and Concentrations  535 
Proteins overexpressed from BryPAT1 (pNL020), EryAIII M6 KS-AT (pEA021), and 536 
BryB M4 KS-AT (pKB114) are present at the approximate size markers with little to no 537 
contaminating bands in the samples.  Protein concentrations of the purified constructs were 538 
adequate for the numerous SPR experiments.  Each SPR experiment required approximately 30 539 
ng of protein. From 2 liters of culture, pNL020 had a yield of 435.17 µg /mL of protein.  pEA021 540 
had 365.4 µg/mL, while pKB114 had the best yield with 548.8 µg /mL of protein.  541 
2.3.1.3 SPR Experiments of pNL020 with pKB114 and pEA021 542 
Initially, SPR experiments were unsuccessful due to unknown non-specific binding on 543 
NTA chip surface.  Once protein constructs were cross-linked immobilized onto the NTA chip 544 
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experimental data was more valid.  Surface density of protein attachment to the NTA chip for 545 
pKB114 was 236.3 RU while pEA021 was 153.6 RU.  Data for the KD values obtained during 546 
the SPR experiments with pNL020 as the analyte were plotted response (response units) versus  547 
concentration (M) (Figure 2.3 & 2.4).  KD raw data of binding affinities for each experiment was 548 
recorded (Table 2.2).  BryAT1 (pNL020) binding affinities to EryAIII M6 (pEA021) were 549 
normalized to the KD values of BryB M4 (pKB114) interaction with BryAT1 (pNL020) (Table 550 
2.3).  Normalized values ranged from 0.68 to 23.98 with an average of 7.48.  Standard deviation 551 
of these values was 9.33. 552 
 553 
 554 
 555 
 556 
pKB11-4 exposed to 0 µM, 0.117 µM, 0.234 µM, 0.4675 µM, 0.935 µM, 1.84 µM, 3.75 µM, 7.5 µM, and 15 
µM of pNL020 plotted with response units (RU) versus concentration in molarity (M). KD value of 2.30E-7. 
Figure 2.3 : SPR Experiment of BryBM4 KS-AT (pKB114) versus BryPAT1 (pNL020) 
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 557 
 558 
 559 
 560 
 561 
   Table 2.2: KD Values of SPR cycle data from BryAT1 versus pKB114 and pEA021 562 
 563 
KS-AT Construct KD Value 
pKB114 pEA021 
5.23E-08 3.55E-08 
8.25 E-09 3.02E-09 
2.30E-07 1.34E-07 
6.97E-09 8.22E-08 
2.44E-08 5.84E-07 
 564 
 565 
 566 
Figure 2.4: SPR Experiment of Ery AIII M6 KS-AT (pEA021) versus BryPAT1 (pNL020) 
pEA021 exposed to 0 µM, 0.117 µM, 0.234 µM, 0.4675 µM, 0.935 µM, 1.84 µM, 3.75 µM, 7.5 µM, and 15 µM 
of pNL020 plotted with response units (RU) versus concentration in molarity (M). KD value of 8.221E-8. 
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 567 
                             Table 2.3: SPR data normalized to pKB114 568 
pEA021 KD 
normalized                           
to pKB114 
0.68 
0.37 
0.58 
11.79 
23.98 
Average KD 
7.48 
Standard Deviation 
9.33 
 569 
 570 
 571 
 572 
2.4 Discussion 573 
KD values are unitless numbers described as if they have molar units of concentration.  574 
Non-covalent interactions using ranged from picomolar to nanomolar for the strongest 575 
interactions while millimolar is found with weaker interactions.  Signaling proteins binding to 576 
molecules usually have KD values in the micromolar range (Kuriyan, 2008).  Binding events in 577 
the SPR experiments show that BryAT1 (pNL020) does interact in the interdomain region 578 
between KS and AT in EryAIII M6 (pEA021) and BryB M4 (pKB114).  KD values range from 579 
10-7 to 10-9 which fall into the micromolar to nanomolar range and could indicate successful 580 
binding of the BryAT1 to the KS-AT interdomain regions.  Previous research has shown that 581 
BryAT1 has the ability to load a malonyl-CoA onto module BryBM4 and EryAIII M6 (Lopanik 582 
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et al., 2008) but the mechanism for doing so has not been elicited.  The potential binding events 583 
in the KS-AT interdomain region could be region of the module in which the BryAT1 interacts to 584 
load the malonyl-CoA to the growing nascent polyketide chain.  Specific amino acid residues 585 
that are involved in the potential binding events are unknown but alignments of the KS-AT 586 
interdomain regions of BryBM4, EryAIII M6, and Pik AIV M6 (Figure 2.1) show different 587 
amino acids that could be used for recognition by the trans-AT.  BryBM4 and EryAIII M6 have 588 
a leucine in position 6 and 48 while Pik AIV M6 has a valine and an alanine, respectively.  Also, 589 
amino acid residue 55 is a serine for Pik AIV M6 while BryB M4 and Ery AIII M6 have glycine.  590 
While the leucine, alanine, and valine are all hydrophobic amino acids and usually found on the 591 
core backbone of the protein, they do differ in size slightly which could cause conformational 592 
changes in the protein.  The difference of a glycine to a serine could be more impactful due to the 593 
change from a hydrophobic amino acid to a polar amino acid that can participate in hydrogen 594 
bonding.  The Pik AIV M6’s serine at residue 55 could have properties that would create 595 
conditions where the BryAT1 could not interact with the module.  596 
2.5 Conclusion 597 
 KD values show differences in BryAT1’s ability to interact with BryB M4 and Ery AIII 598 
M6 with normalized value of 7.48.  The data also indicates that protein-protein interactions could 599 
be occurring in this region of the PKS module.  Successful cloning and overexpression of the Pik 600 
AIV M6 KS-AT region would help to further provide evidence for this hypothesis.  Binding 601 
affinity data of Pik AIV M6 KS-AT region exposed to BryAT1 could show if interactions are 602 
possible and if so, potential amino acids that might be involved.  Site-direct mutagenesis of the 603 
amino acid residues of interest would also help to demonstrate which amino acids appear to be 604 
involved in the protein-protein interactions.  SPR experiments would be repeated once the 605 
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correct substitutions have been made in these areas to determine changes in the binding 606 
affinities.  Changes in SPR data from amino acid substitutions would supplement this idea. 607 
 608 
 609 
 610 
 611 
 612 
 613 
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 616 
 617 
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 625 
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3 IDENTIFY AND COMPARE PROTEIN KINASE C C1B DOMAINS FOUND IN 628 
BUGULA SPP. 629 
 630 
3.1 Introduction  631 
Natural products produced by microorganisms can be potent prokaryotic and eukaryotic cell 632 
effectors.  For instance, the anticancer compound epothilone produced by the myxobacterium 633 
Sorangium cellulosum inhibits microtubule assembly, and salinosporamide, isolated from the 634 
marine bacteria Salinispora spp. inhibits proteasome function (Cragg & Newman, 2013).  Thus, 635 
the majority (75%) of approved therapeutic agents are either natural products or their derivatives 636 
(Newman & Cragg, 2016), most of which are produced by microorganisms.  In many cases, 637 
natural products obtained from a metazoan are actually produced by a microbial symbiont 638 
(reviewed in (Piel, 2009)).  One example of this is the compound rhizoxin, that is associated with 639 
the fungus that produces rice blight.  This compound was shown to be produced by a 640 
endosymbiotic bacterium that associates with the fungus (Partida Martinez & Hertweck, 2005). 641 
Rhizoxin was investigated as an anticancer agent because of its ability to bind tubulin (Hendriks 642 
et al., 1992).  As the fungal host possesses tubulin, the question of how the host is able to grow 643 
in the presence of bacterially-produced rhizoxin arose.  Interestingly, the fungal tubulin protein 644 
was found to possess a critical amino acid substitution which decreased the binding affinity of 645 
rhizoxin (Schmitt et al., 2008).  Further, this amino acid substitution was absent in related fungal 646 
strains that did not host the symbiotic bacterium.   647 
Bugula neritina is the source of the bryostatins, macrocyclic polyketides that modulate 648 
protein kinase C activity.  The bryostatins bind with high affinity to the regulatory C1b region of 649 
PKC (Wender et al., 1988, Wender et al., 2011). The bryostatins have been shown to be 650 
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produced by an uncultured symbiont, “Cand. E. sertula.”  B. neritina is a complex of multiple 651 
closely related sibling species (Davidson and Haygood 1999, McGovern and Hellberg 2001), and 652 
interestingly, some individual colonies have been shown to not possess the symbiont (Linneman 653 
et al. 2014).  Investigations into other species of Bugula have demonstrated that some possess a 654 
related symbiont that produces bryostatin-like molecules (B. simplex, Lim and Haygood 2004), 655 
whereas others possess a related symbiont that does not produce bryostatin-like molecules (B. 656 
pacifica, B. turbinata, Lim-Fong et al. 2008), and some do not possess a symbiont or bryostatins 657 
(B. stolonifera, some colonies of B. neritina, Woollacott 1981, Linneman et al. 2014).  This 658 
variation in symbiont/bryostatin presence among closely related Bugula species provides an 659 
opportunity to investigate the impact of host-symbiont coevolution in the presence of the 660 
symbiont-produced natural products.  As bryostatins modulate PKC activity, it is possible that 661 
PKCs in hosts with symbiont-produced bryostatins respond differently to their presence as a 662 
result of coevolution, and the PKC-affected pathways could influence the Bugula spp. systems 663 
and physiology.  I hypothesize that PKCs in Bugula neritina and other Bugula spp. that have 664 
symbiont-produced bryostatins have evolved under different selection pressures than PKCs in 665 
Bugula spp. without bryostatins.   666 
To investigate this possibility, PKC C1b domains were sequenced and compared in B. 667 
neritina (aposymbiotic and symbiotic) colonies as well as other Bugula spp. that do and do not 668 
possess the symbiont and/or the bryostatins to determine if PKCs from Bugula species that 669 
evolved in the presence of bryostatins have modified bryostatin-binding domains.  It is possible 670 
that variations in the C1b domain may result in differing binding capabilities between PKC 671 
isoforms and bryostatins within Bugula species.  In order to analyze these interactions, PKC C1b 672 
domains were compared among colonies of differing Bugula spp.  Because very little sequence 673 
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data for B. neritina exists, a transcriptomics approach was used to assess the diversity of PKCs. 674 
PKC C1b genes were confirmed via PCR amplification using primers designed according to the 675 
transcriptomic data and sequenced. This approach was also used to obtain partial sequences of 676 
PKCs from the other species of Bugula. Sequences were analyzed and amino acid alignments 677 
evaluated for conserved amino acids between the species and symbiotic types.  I hypothesize that 678 
PKC C1b domain regions will vary in amino acid residues between each Bugula species. 679 
Differences in C1b domain sequences in host species would support the hypothesis that the host 680 
PKCs have evolved under different conditions such as the presence of the symbiont-produced 681 
bryostatin compounds. 682 
 683 
3.2 Materials and Methods 684 
3.2.1 Sample Collection and Genotyping of Bugula neritina  685 
Bugula spp. were collected from the Morehead City, NC, preserved in RNA Later, and 686 
frozen at -20ºC. The collected colonies were identified to species using the host mitochondrial 687 
cytochrome c oxidase I sequence (Davidson & Haygood, 1999, McGovern & Hellberg, 2003).  688 
Genomic DNA was extracted using ZR Fungal/Bacterial DNA Miniprep Kit (Zymo Research 689 
Corp., Irvine, CA, USA) and quantified using a Nanodrop™ ND-1000 spectrophotometer 690 
(Nanodrop™ Technologies, Inc., Wilmington, Delaware, USA).  DNA was PCR amplified using 691 
Phire Hot Start II DNA polymerase (Thermo Scientific, Pittsburgh, Pennsylvania, USA) and 692 
BnCOI F and BnCOI R primers (Table 3.1) (Linneman et al., 2014). PCR reactions were carried 693 
out by initial denature at 98°C for 30s sec, with 35 cycles of denatured at 98°C for 5 sec, 694 
annealed for 30 sec at 59°C, and elongated at 72°C for 25 sec, and final extension of 72°C for 2 695 
min.  PCR amplicons were digested for 30 minutes at 37ºC with AseI and AluI (NEB, Ipswich, 696 
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MA, USA) and then deactivated at 80ºC for 20 minutes.  Digested products were separated using 697 
agarose gel electrophoresis and analyzed for band sizes specific to either Type S or Type N B. 698 
neritina.   699 
 700 
 701 
Table 3.1 Primers used in Genotyping of Bugula spp. 702 
 703 
 704 
3.2.2 Transcriptomics of Bugula neritina 705 
Transcriptomic data was performed previously (Mathew et al., 2016) by symbiotic and 706 
naturally symbiont-reduced Type S B. neritina zooids preserved in TRIzol reagent (Invitrogen, 707 
Carlsbad, California, USA).  Total RNA was extracted as per the manufacturer’s instructions and 708 
purified using RNeasy Mini kit (Qiagen, Valencia, California, USA), and RNase-free DNase I 709 
treated to remove contaminating genomic DNA.  RNA quality was determined using an Agilent 710 
2100 Bioanalyzer system (Agilent Technologies, Santa Clara, California, USA) and found to 711 
have a RNA integrity number (RIN) value of 8. The purified total RNA was processed according 712 
TruSeq RNA Sample Preparation Kit (Illumina, San Diego, California, USA) procedure for 713 
preparation of mRNA library.  The adapter-ligated cDNA library was hybridized to Illumina 714 
Name Sequence (5’→3’) Target 
Product 
size 
(bp) 
Annealing 
Temperature 
BnCOI F ACAGCTCATGCATTTTTA B. neritina COI 
gene 
469 59°C 
BnCOI R CATTACGATCGGTTAGTAG 
LCO 1490 F GGTCAACAAATCATAAAGATATTGG Mitochondrial 
(COI) genes  
710 50°C 
HCO 2198 R TAAACTTCAGGGTGACCAAAAAATCA 
MT 16SAR F CGCCTGTTTATCAAAAACAT Mitochondrial 
16S gene 
552 50°C 
MT 16SCB R CCGGTCTGAACTCAGAT 
44 
flow cell and sequenced on an Illumina HiSeq 2500 sequencing platform (Illumina, San Diego, 715 
California, USA) at the Integrated Genomics Facility (Georgia Regents University Cancer 716 
Center, Augusta, Georgia, USA). The paired-end reads were assembled De Novo using Trinity 717 
software package (version r2013-02-25)(Grabherr et al., 2011), and the assembled contigs were 718 
annotated by performing BLASTx searches (Translated Query-Protein Subject BLAST 2.2.26+) 719 
against the Swiss-Prot database. Sequences identified as PKCs were further analyzed by 720 
MotifScan (ExPASy) to identify relevant domains (Mathew et al., 2016).  Based on the 721 
sequences identified as PKCs, B. neritina-specific PKC primers were designed (Table 3.2).  722 
 723 
3.2.3 Bugula spp. RNA extraction and cDNA synthesis 724 
Once colonies were genetically-typed, 50 mg of each Bugula colony was washed with 725 
washed in PBS buffer (Harbor, 2006). The sample was split into two 25 mg aliquots and 726 
transferred into separate tubes of 500 µL of TRIzol reagent for homogenization.  After ten 727 
rounds of homogenization on ice using a sterile pestle, split samples were recombined and RNA 728 
extracted. Total RNA was extracted and purified per TRIzol manufacturer’s protocol.  After 729 
RNA extraction, samples were purified of any PCR inhibitors by using a resin in OneStep PCR 730 
inhibitor removal kit (Zymo Research Corp., Irvine, CA, USA). Samples were subjected to an 731 
additional DNase I treatment for 1 hour at 37°C (Roche, Mannheim, Germany) and reaction was 732 
quenched with the addition of 0.5 M EDTA. Samples were further purified using RNA Clean & 733 
Concentrator™ (Zymo Research Corp., Irvine, California, USA). The Nanodrop 734 
spectrophotometer was used to quantify RNA concentrations and samples were stored at -80°C. 735 
Single stranded cDNA was generated from approximately 2 µg of total RNA using random 736 
hexamer primers and the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, 737 
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CA, USA). No reverse transcriptase enzyme controls were performed to ensure no genomic 738 
DNA contamination. Confirmation of synthesized cDNA was performed using PCR with 739 
mitochondrial 16S gene primers (Braga et al., 1999) (Table 3.1) and Phire Hot Start II 740 
polymerase. PCR reactions were carried out by initial denature at 98°C for 30s sec, with 35 741 
cycles of denatured at 98°C for 5 sec, annealed for 30 sec at 50°C, and elongated at 72°C for 25 742 
sec, and final extension of 72°C for 2 min.   743 
3.2.4 Amplification of PKC genes in Bugula neritina and Bugula spp. 744 
Using transcriptomics data, primers specific to PKC isomers were designed to flank C1b 745 
domain regions according to B. neritina Type S C1b domain data using the NCBI Primer-746 
BLAST (Ye et al., 2012) tool (Table 3.3). The α, ε, and δ isomers were targeted for amplifying 747 
the C1b domain region while ι isomer was amplified for the absence of the C1b domain. cDNA 748 
using Phire Hot Start II DNA polymerase  and B. neritina-specific PKC primers (Mathew et al., 749 
2016).  PCR reactions were carried out by initial denature at 98°C for 30s sec, with 35 cycles of 750 
denatured at 98°C for 5 sec, annealed for 30 sec (temperature varied by primer set), and 751 
elongated at 72°C for 25 sec, and final extension of 72°C for 2 min.  PCR amplicons were 752 
analyzed by agarose gel electrophoresis, and reactions resulting in single amplicons were column 753 
purified (GeneJET PCR Purification kit). PCR reactions yielding multiple PCR amplicons will 754 
be purified using gel purification (GeneJET Gel Extraction kit) and were sequenced at the DNA 755 
Analysis Facility at Yale University, New Haven, CT, USA.   756 
3.2.5 Sequence Analysis 757 
 Sequences of the amplified PCR products were edited for consensus sequences. The  758 
C1b domain sequences were identified by domain analysis and aligned with other known C1b 759 
domain sequences from multiple species using ClustalX v2.0 (Larkin et al., 2007). Genetic 760 
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relationships of the PKC C1b domain isomers were assessed via phylogenetic analysis using  761 
MEGA (Tamura et al., 2013). 762 
                           Table 3.2 Primers used in identification of PKC isoforms in Bugula spp. 763 
 764 
 765 
Combinations of PKC C1b domain primers 
DNA 
Size 
(bp) 
AA 
length 
Target 
BnPKCd_1f ATGTCGGTGGTTGGTTTTATCC 
976 325 
B. neritina 
PKC δ type BnPKCd_1000r TTGCCTGATATTCTTCATCATCC 
BnPKCe_1f ATGGTATATTTCACTGGCCGTCTAC 
1026 311 
B. neritina 
PKC 
ε type 
BnPKCe_1027r AAGTGGATGATTCGCTGAATGAC 
BnPKCe_1f ATGGTATATTTCACTGGCCGTCTAC 
1084 315 
BnPKCe_1085r GTGATGAGTTCACGAGAATTCC 
BnPKCe_405f TGAGAGTTATACGCCCCAACTC 
622 207 
BnPKCe_1027r AAGTGGATGATTCGCTGAATGAC 
BnPKCe_484f GACAGGATGTTCAAGGAGAAAGAC 
543 154 
BnPKCe_1027r AAGTGGATGATTCGCTGAATGAC 
BnPKCe_466f ATGTTCAAGGAGAAAGACGTGAG 
561 164 
BnPKCe_1027r AAGTGGATGATTCGCTGAATGAC 
BnPKCa8617_10f CACAAAGTCTCTCTCTCAAGAC 
1000 329 
B. neritina 
PKC 
α type 
BnPKCa8617_1000r GAAGTTTATACCAGCTGTCCAAC 
BnPKCa8617_40f ATGAGTTCCAGTGTGCAGGAGC 
541 180 
BnPKCa8617_581r GTGATTTCTCTGTCACTGTGAG 
BnPKCa66800_1f ATGATGGAGGAGGATCCAGTAG 
833 273 
BnPKCa66800_834r CAACAGCTTGAACCACCCTCTAG 
BnPKCa66800_445f GAGAGACGAGGAAGGATTCAG 
389 130 
BnPKCa66800_834r CAACAGCTTGAACCACCCTCTAG 
BnPKCι_6484_174f AGACCCCTGTACCATCTCCTC 
546 182 
B. neritina 
PKC 
ι type 
BnPKCι_6484_719r TTAGCATAGCTGCCTCGCC 
BnPKCι_6484_237f CAAGGATCCCGAGCTAACAG 
432 144 
BnPKCι_6484_668r CCGATAGCACCAGCATCTGA 
BnPKCι_6484_77f GCTCTATTACCTACAACCGGC 
901 301 
BnPKCι_6484_977r TCTTCTGGCAGCCTTCTTTG 
BnPKCι_6484_962f GAAGGCTGCCAGAAGATCAC 
692 231 
BnPKCι_6484_1653r CTCTGACTGGTCTATCTTCGC 
47 
 766 
3.3 Results 767 
3.3.1 Confirmation of sequences 768 
Transcriptomics analysis of Type S B. neritina sequences yielded at least 5 expressed 769 
PKC isoforms.  Bioinformatic analysis of the PKC contigs indicated that contigs 4634 and 16020 770 
were homologous to conventional αPKCs. The two novel PKCs found were contig 12712, a δ 771 
isoform, and contig 16336, an ε isoform.  The analysis also specified one atypical ι-type PKC, 772 
contig 6484 (Mathew et al., 2016). RT-PCR analysis of symbiotic B. neritina Type S confirmed 773 
the presence of these PKC isoforms (Mathew et al., 2016). The isomers of conventional αPKCs, 774 
novel PKCs (δ and ε), and atypical ι-type PKC were successfully amplified in B. neritina type S 775 
and sequenced. Sequences analyzed via highest hit in BLASTp (Altschul et al., 1997) confirmed 776 
that contigs 4634 was a 59% identity match to a PKC α isoform found in Macaca mulatta, while 777 
contig 16020 matched with 61 % identity to PKC α type-like isoform X1in Haplochromis 778 
burtoni. The highest BLASTp hit for contig 12712 shared a 55% sequence match with a protein 779 
kinase C δ type-like characterized in Saccoglossus kowalevskii. Contig 16336’s highest hit was 780 
63 % identical to a calcium-independent protein kinase C in Aplysia californica. The atypical ι 781 
PKC isomer contig 6484 was found to have a 72% identity match to its highest hit of Lymnaea 782 
stagnalis (Table 3.4). Confirmed Bugula neritina Type S PKC sequences were submitted to 783 
National Center for Biotechnology Information (NCBI) Genbank® database (Benson et al., 784 
2013). Contigs of all 5 B. neritina PKC cDNA sequences have been issued accession numbers 785 
KM047237 to KM047241. 786 
 787 
 788 
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Table 3.3 PKC homologs identified by Bugula neritina transcriptome sequencing 792 
 793 
 794 
 795 
3.3.2 Analysis of C1b domains in B. neritina PKC isoforms  796 
Sequences of PKC C1b domains, 50 amino acids in length, from the Type S B. neritina 797 
were compared for differences in the amino acid residues that could be important for PKC 798 
activation.  The C1b domains of the highest BLAST hits and nearest neighbors of the 5 contigs 799 
were compared to those from B. neritina.  Using MegAlign, the amino acid sequences of C1b 800 
domains were aligned and compared to identify conserved residues and difference between the 801 
PKC isoforms of B. neritina and BlastX highest hits (Figure 3.1).  All contigs of conventional, 802 
Contig 
DNA 
length 
Amino 
acid 
length 
Highest hit (by blastp) e-value 
% 
identity 
PKC 
isoform 
GenBank 
accession no. 
4634 2130 710 
Protein kinase C α type  
(Macaca mulatta) 
0.0 59% 
Conventional 
α 
NP_001247662 
16020 2031 677 
Protein kinase C α type-like isoform 
X1 (Haplochromis burtoni) 
0.0 61% 
Conventional 
α 
XP_005942808 
12712 2091 697 
Protein kinase C δ type-like 
(Saccoglossus kowalevskii) 
0.0 55% 
Novel 
δ 
XP_002740313 
16336 2148 716 
Calcium-independent protein kinase 
C (Aplysia californica) 
0.0 63% 
Novel 
ε 
NP_001191401 
6484 1710 570 
Atypical protein kinase C  
(Lymnaea stagnalis) 
0.0 72% 
Atypical 
ι 
BAK09601 
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novel and atypical PKCs had several regions of highly conserved regions.  Residues 3 in the 803 
novel ε PKC C1b domains exhibit several variations.  PKC α isforms show variability at residues 804 
5 and 43. PKC δ isoforms have dissimilarities at position 45 but the most obvious difference is at 805 
position 12. B. neritina differs with a histidine at position 12 unlike the rest of the PKC δ C1b 806 
domains shown. Also, while the PKC δ is also a novel PKC, it has a higher homology with the 807 
conventional α PKC than that of the ε.  Phylogenetic analysis (Figure 3.2) depicts the genetic 808 
relationships of the confirmed B. neritina PKC c1b domains in comparison with their Blastx 809 
highest hits. The constructed tree shows that PKC conventional α and novel δ are the more 810 
closely related while the novel ε has less homology to δ. PKC ι isoforms are the most distantly 811 
related. 812 
 813 
 814 
Figure 3.1: Alignment of C1b domains from B. neritina PKC isoform contigs and highest BlastX hits 
50 
 815 
 816 
Figure 3.2:  Phylogenetic tree of B. neritina PKC isoform contigs and highest BlastX hits 
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3.4 Discussion 817 
From the transcriptome sequences, five contigs from differing isoforms of PKCs were 818 
identified in B. neritina cDNA sequences.  These genes have a high degree of homology with a 819 
diverse group of organisms including Macaca mulatta primate, Haplochromis burtoni fish, 820 
Saccoglossus kowalevskii hemichordates, and molluscs spp. Aplysia californica and Lymnaea 821 
stagnalis (Table 3.3). mSeveral residues such as His1, Leu21, Gly23, Cys50, positions 14-18 are 822 
conserved amongst all of the sequences from B. neritina and the other organisms.  In residues 4 823 
and 10, novel PKC δ C1b domain to have a higher homology with conventional PKC α than the 824 
novel ε isoform PKCs (Figure 3.1).  Phylogenetic analysis (Figure 3.2) confirms that PKC δ B. 825 
neritina contig 12712 is more closely related to the PKC α conventional contigs of 4634 and 826 
16020; however, there was not strong bootstrapping to support.  While the atypical PKC ι 827 
isoforms were confirmed in B. neritina (Table 3.2), this group only contains a C1a domain in the 828 
DAG binding region and lacks the C1b domain where bryostatin-1 binds to activate PKC 829 
phosphorylation.  PKCs δ and ε are more similar at amino acid position 7 and 26 than the α 830 
isoform.   831 
The histidine amino acid residue at position 12 of B. neritina contig 12712 and C. teleta 832 
differs with a serine, the deviation at this position while all other PKCs have a threonine.  833 
Histidine, serine, and threonine are all polar amino acids; however, the histidine side chain is 834 
positively charged while serine and threonine are uncharged.  Also, mouse nPKC δ had potential 835 
to participate in hydrogen binding at carbonyl of Met9, the amino of Thr12, the carbonyl of 836 
Leu21, and the amino of Gly23 (Kimura et al., 1999). PKC δ C1b domain of B. neritina shows 837 
the last Leu21 and Gly23 are conserved; however, Met9 is an Ile and Thr12 is a His (Figure 3.1).   838 
The difference in the amino acids could be due to evolutionary change in B. neritina due to the 839 
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presence of bryostatin compounds produced by the symbiont.  Experimental analysis of the 840 
bryostatins ability to bind the B. neritina C1b domains, with amino acid exchanges, could 841 
highlight importance of specific residues for PKC activation.   842 
 843 
3.5 Conclusion 844 
Amino acid residues involved in the activation of PKC’s in B. neritina C1b domain 845 
sequences are unknown.  Analysis of the C1b domains could discover which amino acids 846 
involved in binding of the natural product bryostatin to the DAG binding region.  SPR binding 847 
affinity experiments of B. neritina C1b domains and other organisms could detect specific 848 
residues involved in this recognition.  Sequence data of PKC δ has identified Thr12 as well 849 
conserved among the conventional C1b domains; however, B. neritina nPKC δ and the annelid, 850 
Capitella teleta differ at that position with a histidine and serine, respectively.  In addition, 851 
variations in the Met9 residue of the cPKC α domain sequences could also provide areas for 852 
binding analysis to bryostatins.  Experimental analysis of bryostatin binding to C1b domains 853 
with modified amino acid residues will allow us to understand the importance of these residues 854 
for PKC activation.  Previous research has suggested that bryostatin 1 binds to the peptide 855 
backbone of the protein and not functional groups.   856 
Further work should be conducted to identify the PKC C1b domains in other Bugula spp. 857 
to detect differences in sequences.  Possible differences could be due to an evolutionary change 858 
due to the presence of bryostatins. Other Bugula spp. such as B. pacifica do not contain a 859 
bryostatin-producing symbiont.  To characterize the effects bryostatin natural products have on 860 
the PKC C1b domains of the host Bugula neritina, with bryostatins, and other Bugula spp., 861 
without bryostatins, to determine if these amino acids could be involved in bryostatin activation.  862 
53 
Amino acid residues of 9Ile and 12His could be areas for amino acid substitution to provide 863 
further evidence of activation due to binding at the positions. 864 
 865 
 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
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4 QUANTIFY BRYOSTATIN AFFINITY FOR BUGULA SPP. PKC C1B DOMAINS 885 
 886 
4.1 Introduction 887 
Bugula spp. vary in symbiont and bryostatin status with some species possessing a 888 
symbiont that produces bryostatins, some species possessing a closely-related symbiont that does 889 
not produce bryostatins, and some species with no symbiont or bryostatins.  The presence of 890 
bryostatin could directly affect the Bugula host.  PKC C1b domain gene evolution could have 891 
occurred due to the presences of the natural products. Through the identification of PKC C1b 892 
domains in Type S B. neritina and Bugula spp. possible amino acids changes can be identified.  893 
The identification of amino acid variations between species with bryostatins and without could to   894 
understanding of bryostatin affinity for the C1b domains.   895 
Sequence differences in the Bugula spp. C1b domain regions could result in different 896 
binding affinities that are adaptations to the presence of symbiont-produced bryostatins.  To 897 
investigate this, C1b domain regions of PKC isoforms were amplified from Bugula spp. and 898 
sequenced. C1b domains from differing PKC isoforms were cloned into a vector for protein 899 
expression and the resulting proteins were purified.  Their binding affinity for bryostatin and 900 
PMA, a similar PKC activator, were quantified.   Previous research found that PMA activates 901 
PKCs by predominately phosphorylating serine residues (Roush et al., 1999).  Surface plasmon 902 
resonance was utilized to assess binding differences by quantifying the bryostatin interactions 903 
among the Bugula spp. C1b domains. I hypothesize that binding affinities in aposymbiotic 904 
colonies will be higher than symbiotic colonies.  Prolonged exposure to bryostatins in symbiotic 905 
Bugula species could elicit lower affinities so that the PKC can still be activated.  Lower binding 906 
55 
affinities in symbiotic than aposymbiotic Bugula spp. will confirm that PKCs in Bugula spp. 907 
with symbiont-produced bryostatins have co-evolved and adapted to the presence of bryostatin.   908 
Using alignments of the C1b domains of the Bugula spp. (Figure 3.2), site directed 909 
mutagenesis was performed on amino acid residues of PKC C1b domains that vary in sequence.  910 
Bugula spp. C1b domains with high and low levels of bryostatin binding and that differ in amino 911 
acid residues will be mutated into amino acids more similar to PKC C1b domains of opposite 912 
binding affinities.  I hypothesize that changes in amino acids could alter bryostatin binding 913 
affinity to the PKC C1b domain.  Subsequent SPR experiments will allow for data on the 914 
changes in bryostatin binding affinities in overexpressed C1b domain proteins of Bugula spp. 915 
symbiont-produced bryostatins, symbionts with no bryostatins, and aposymbiotic colonies.  916 
Identification of key amino acids for PKC C1b bryostatin binding could lead to understanding 917 
host-symbiont interactions and the ability of that interaction to, over time, result in co-evolution 918 
to increase host fitness.   919 
 920 
 921 
4.2 Materials and Methods 922 
4.2.1 Identification of PKC C1b domain in Bugula spp. 923 
4.2.1.1 Sample collection and Genotyping 924 
Bugula spp. of interest were collected from the Pacific Northeast coastlines at Skyline 925 
marine center, WA, Deception Pass, WA, Newport marina, WA, Charleston, OR, and Coos Bay, 926 
OR. Bugula spp. were also collected from Atlantic Northwest coastlines in Woods Hole (Eel 927 
pond), MA, Gloucester, MA, and Portland, MA. All collected samples were preserved in RNA 928 
Later and frozen at -20ºC.  Genomic DNA was extracted using ZR Fungal/Bacterial DNA 929 
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MiniPrep™ kit (Zymo Research Corp., Irvine, CA, USA) and PCR amplified as previously 930 
described using mitochondrial cytochrome c oxidase, primers LCO1490 and HCO 2198 (Folmer 931 
et al., 1994) using Phire Hot Start II polymerase.  PCR amplicons were purified using GeneJET 932 
PCR purification and were visualized using gel electrophoresis. The PCR amplicons were 933 
sequenced at the DNA Analysis Facility at Yale University, New Haven, CT, USA. Consensus 934 
sequences were analyzed using BLAST (Altschul et al., 1990) to confirm sample identity. 935 
 936 
4.2.1.2 Amplification of PKC C1b domains in Bugula spp. 937 
Genotyped Bugula spp. colonies were washed with PBS buffer (Harbor, 2006) then 938 
homogenized in TRIzol reagent. Total RNA was extracted per TRIzol manufacturer’s protocol.  939 
Samples were purified using OneStep PCR inhibitor removal kit and a DNase I treatment for 1 940 
hour at 37°C (Roche). Samples were further purified using RNA Clean & Concentrator™ and 941 
quantified using Nanodrop spectrophotometer. Single stranded cDNA was synthesized using 942 
approximately 2 µg of total RNA with SuperScript III First-Strand Synthesis System and random 943 
hexamer primers. No reverse transcriptase enzyme controls were performed to ensure cDNA was 944 
free of genomic DNA contamination. Confirmation of synthesized cDNA was performed using 945 
PCR with mitochondrial 16S gene primers (Braga et al., 1999) (Table 3.1) and Phire Hot Start II 946 
polymerase. 947 
 948 
 949 
 950 
 951 
 952 
57 
 953 
Table 4.1: PKC C1b domain primers used to amplify in Bugula spp. 954 
 955 
 956 
 957 
Primers used in C1b domain amplification were designed according to the sequences of 958 
PKC C1b isoforms from B. neritina. Phire Hot Start II polymerase was used in amplifying 959 
reactions of an initial 98°C for 30s sec, with 35 cycles of denatured at 98°C for 5 sec, annealed 960 
for 30 sec (temperature varied by primer set), and elongated at 72°C for 25 sec, and final 961 
extension of 72°C for 2 min. PCR amplicons were analyzed by agarose gel electrophoresis, and 962 
reactions resulting in single amplicons were column purified. PCR reactions yielding multiple 963 
PCR amplicons were purified using gel purification. Purified PCR amplicons were sequenced at 964 
PKC C1b domain primers 
Name Sequence (5’→3’) Target 
DNA 
Size 
(bp) 
BnPKCd_12712_512f GACAGCCAGTGTTCTGTTCT 
PKC δ C1b 
domain               
(703-852 bp) 
541 
BnPKCd_12712_1052r TGTGCATCCTTGTCTGCG 
BnPKCd_12712_553f GGGCTGAACAAGCAAGGAT 
433 
BnPKCd_12712_985r CATCATCCTCCTCTTCATTTGC 
BnPKCe_16336_517f CAACCAACATTCTGCTCCCA 
PKC ε C1b 
domain               
(706-855 bp) 
529 
BnPKCe_16336_1045r GCTGCAACCTTGAAGAAAGG 
BnPKCe_16336_571f CAAGGTTACCAATGTCAAGTGTG 
418 
BnPKCe_16336_988r TATTACGCAGAGTTGTGGCA 
BnPKCa_4634_128f ACCACAAGTTTGTACCCAGG 
PKC α C1b 
domain               
(325-474 bp) 
543 
BnPKCa_4634_670r GACTGTGTCCGTGACTGTG 
BnPKCa_4634_178f TGCAAAGATTTTATTTGGGGGT 
434 
BnPKCa_4634_611r TTTACGTAGGGGTCAGCCAG 
BnPKCa_16020_84f TCACAAGTTTGTTCCCCGATT 
PKC α C1b 
domain               
(280-429 bp) 
534 
BnPKCa_16020_617r ACACTGTGAATGTGACTACCG 
BnPKCa_16020_150f GGGAGTAATTGGGAAACAAGGT 
417 
BnPKCa_16020_566r TTGACATACGGATCTGCAAGG 
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the DNA Analysis Facility at Yale University, New Haven, CT, USA.  Bugula spp. PKC C1b 965 
domain sequences were confirmed by BLAST and sequence alignments with other C1b domains.  966 
4.2.1.3 Construction of PKC C1b domain Plasmids 967 
PKC C1b domain amplicons were digested with EcoRI and XhoI (NEB, Ipswich, MA, 968 
USA) for 2 hours at 37°C and visualized using gel electrophoresis to ensure proper DNA size. 969 
The digested DNA band was excised and purified using GeneJET gel extraction kit (Thermo 970 
Scientific, Vilnius, Lithuania).  Purified PCR-amplified C1b domains were ligated into EcoRI 971 
and XhoI digested a pET28B vector (Novagen).  The ligated products were transformed into 972 
chemically competent E. coli XL1-Blue (Stratagene) cells, plated on LB agar with 50 µg/mL 973 
KAN, and incubated at 37°C overnight.  Resulting colonies were screened for insert by colony 974 
PCR using T7 and T7 terminator primers and One Taq Polymerase (NEB). Colony PCR 975 
amplicons of PKC C1b domain isoforms with the size of interest were extracted using Zyppy™ 976 
Plasmid Miniprep Kit (Zymo Research Corp., Irvine, CA, USA) and quantified using Nandrop. 977 
Constructs had 6x His-tags located at the N-terminus and the C-terminus of each protein.  978 
 979 
4.2.2 Construction of PKC δ C1b Domain Mutants 980 
4.2.2.1 Site-direct Mutagenesis  981 
Site-directed mutagenesis was used to alter specific amino acid residues of the PKC δ 982 
C1b constructs using primers designed for the position changes.  An exponential amplification 983 
reaction using Q5 Hot Start High-Fidelity 2X Master Mix (NEB, Ipswich, MA, USA) and 984 
approximately 25 ng/µl of construct was performed with initial denaturation at 98°C for 30 985 
seconds, then 25 Cycles at 98°C for 10 seconds, annealing temperature specific to each primer 986 
set for 30 seconds, extension at 72°C 20seconds with a final extension at 72°C for 2 minutes. 987 
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 989 
 Table 4.2: PKC δ C1b Domain Primers for Mutant Constructs 990 
Methylated template DNA was then removed via DpnI digestion at 25°C for 5 minutes.  991 
Resulting products were transformed into transformed into chemically competent E. coli XL1-992 
Blue (Stratagene) cells, plated on LB agar with 50 µg/mL KAN, and incubated at 37°C 993 
overnight. Resulting colonies were screened for insert by colony PCR using T7 and T7 994 
terminator primers and One Taq Polymerase (NEB).  Construct plasmids that were found to have 995 
PKC δ C1b Domain Primers for Mutant Construct 
Name Sequence (5’→3’) Target 
Rat_9MI_f ATAACTACATCAGCCCCACCTTC R. norvegicus C1b domain                         
AA residue  9  M→I Rat_9MI_r AGACCTTGAATCGGTGAG 
Rat_9ML_f CTATAACTACCTGAGCCCCACC R. norvegicus C1b domain                       
AA residue  9  M→L Rat_9ML_r ACCTTGAATCGGTGAGGC 
Bp_9LM_f GCACAACTACATGACACCCACATTC B. pacifica C1b domain                       
AA residue  9  L→M Bp_9LM_r ACTTTCAATCTATGGGGTACATTG 
Bn_9IL_f TCACAATTTTCTGGGGCCTCACTTC B. neritina C1b domain                       
AA residue  9  I→L Bn_9IL_r GGTTTGAATCGGTGAGGAAC 
Bn_41RK_f TGTCACAAGAAATGTGAGAAGCTGATGCC B. neritina C1b domain                       
AA residue  41  R→K Bn_41RK_r GTTGGTGCCACATGCTTC 
Bn_5PV_f CCGATTCAAAGTGCACAATTTTATTGGG B. neritina C1b domain                       
AA residue  5  P→V Bn_5PV_r TGAGGAACATTTATTCCC 
Bn_9IL_12HT_f CCTACCTTCTGTGACCACTGCGG B. neritina C1b domain                       
AA residue  9  I→L   12 H→T Bn_9IL_12HT_r CCCCAGAAAATTGTGAGGTTTGAATCGG 
Bn_8FY_f CCTCACAATTATATTGGGCCTC B. neritina C1b domain                       
AA residue  8  F→Y Bn_8FY_r TTTGAATCGGTGAGGAAC 
Bn_9IM_f ACAATTTTATGGGGCCTCACTTC B. neritina C1b domain                       
AA residue  9  I→M Bn_9IM_r GAGGTTTGAATCGGTGAG 
Bn_12HT_f TATTGGGCCTACCTTCTGTGAC B. neritina C1b domain                       
AA residue  12  H→T Bn_12HT_r AAATTGTGAGGTTTGAATCG 
Bn_9IM_12HT_f CTACCTTCTGTGACCACTGCGG B. neritina C1b domain            
AA residue  9  I→M   12 H→T Bn_9IM_12HT_f GCCCCATAAAATTGTGAGGTTTGAATCGG 
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an insert size of interest were extracted using Zyppy™ Plasmid Miniprep Kit (Zymo), column 996 
purified, and quantified using Nandrop.  Purified plasmids were sequenced at the DNA Analysis 997 
Facility at Yale University, New Haven, CT, USA.  Substituted amino acid residues PKC C1b 998 
construct sequences were analyzed by C1b domain sequence comparison.  999 
4.2.3  Overexpression 1000 
4.2.3.1 Cell Growth and Induction 1001 
Bugula neritina PKC δ C1b (pKBbn2512), Bugula pacifica PKC δ C1b (pKBbp311), 1002 
Rattus norvegicus PKC δ C1b (pKBrt2511), and B. neritina PKC δ C1b substitution mutant 1003 
(pKBbn2512_H12T) plasmids were transformed in chemically competent E. coli BL21 1004 
(Novagen) cells.  Plasmids were initially grown in 50 mL tubes with 10 mL of Luria Bertani- 1005 
Miller broth (LB) with 50 µg/mL KAN overnight at 37°C shaking at 250 rpm.  A second pass of 1006 
the cells were grown in 2 liter flasks with 1.5 liters of terrific broth (TB) with 5% glycerol 1007 
supplemented with 50 µg/mL KAN at 25°C with shaking at 200 rpm.  Cell densities were 1008 
measured every hour until cells reached optical density (OD600) of 1.  Flasks were then incubated 1009 
at 16°C for 1 hour to acclimate cells to the lower temperature. BL21 cells were induced with 1010 
100mM IPTG and incubated shaking at 200 rpm at 16°C for 24 hours. 1011 
4.2.3.2 Extraction of Recombinant PKC C1 domain proteins 1012 
Each construct’s cells were centrifuged at 4,000 rpm at 4 °C for 25 minutes.  The protein 1013 
was extracted using BugBuster® (Merck Millipore, Darmstadt, Germany) reagent specifications. 1014 
BugBuster® was diluted 1:10 with QIAexpressionist (Qiagen, Valencia, California, USA) lysis 1015 
buffer pH 8 consisting of 50mM sodium phosphate (monobasic), 300mM sodium chloride, and 1016 
10mM imidazole. Cells were thoroughly resuspended in the 1X Bugbuster® and incubated with 1017 
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slight agitation for 1 hour at room temperature.  The soluble and insoluble protein fractions were 1018 
separated by centrifugation at 4,000 rpm for 40 minutes.   1019 
4.2.4 Purification of PKC C1b domains 1020 
4.2.4.1 Ni-NTA purification 1021 
The target proteins were purified from the soluble fractions with Ni-NTA 1022 
chromatography.  Ni-NTA chromatography was performed by mixing the soluble protein 1023 
fraction with Ni-NTA agarose (Qiagen) and incubating samples at 4°C with slight agitation for 1 1024 
hour. Protein samples were added to a column where cell lysate was removed by gravity flow.  1025 
The column was washed twice with wash buffer pH 8 consisting of 50 mM sodium phosphate, 1026 
300mM sodium chloride, and 20mM imidazole.  Protein was eluted from the column using 1027 
elution buffer pH 8 consisting of 50 mM sodium phosphate, 300mM sodium chloride, and 1028 
250mM imidazole.  Protein fractions were separated using SDS-PAGE.   1029 
4.2.4.2  Thrombin Cleavage of 6X His-tag from BryAT1 1030 
pKBbn2512, pKBbn2512_H12T, pKBbp311, and pKBrt2511 were concentrated using 1031 
Amicon® Ultra-4 centrifugal filters (Merck Millipore Ltd.) for 30 minutes at 4,000 rpm at 4°C.  1032 
All proteins were exchanged into calcium chloride buffer consisting of 50mM Tris-HCl, pH 8, 1033 
and 10 mM calcium chloride by centrifuging at 4,000 rpm for 30 minutes at 4°C in Amicon® 1034 
Ultra-4 filter.  Thrombin cleavage was performed according Thrombin CleanCleave™ Kit 1035 
(Sigma-Aldrich) protocol at room temperature with gentle agitation for 4 hours.  Proteins were 1036 
recovered by supernatant collection using room temperature centrifugation at 2,500 rpm for 5 1037 
minutes.  1038 
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4.2.4.3 Size-Exclusion Chromatography 1039 
pKBbn2512, pKBbn2512_H12T , pKBbp311, and pKBrt2511 were purified with size-1040 
exclusion chromatography (SEC) using a fractionation range of 3000–70000 Da.  Column was 1041 
packed using 15 mL of Superdex® 75 agarose beads (Sigma-Aldrich, St. Louis, Missouri, USA) 1042 
in a XK16/20 (GE, Uppsala, Sweden) glass column.  SEC purification running buffer consisted 1043 
of 0.2µm filtered 50mM monobasic sodium phosphate, 50mM dibasic sodium phosphate, and 1044 
150mM sodium chloride.  Purification was performed on ÄKTA explorer 100 (GE Healthcare, 1045 
Malbourgh, MA, USA) at 0.4 mL/min flow rate for approximately 1 hour.  All protein fractions 1046 
were visualized using SDS-Page to ensure removal of unwanted proteins. 1047 
4.2.4.4  Concentration and Quantification 1048 
Protein fractions with band of interest were concentrated using Amicon® Ultra-4 1049 
centrifugal filters for 30 minutes at 4,000 rpm at 4°C.  Buffer exchange was performed using 1050 
HBS-P + 0.1% DMSO buffer consisting of 10mM 4-(2-hydroxyethyl) piperazine-1-1051 
ethanesulfonic acid (HEPES) pH 7.4, 150mM sodium chloride, 0.05% Tween 20, and 0.1% 1052 
DMSO by centrifugation for 40 minutes at 4,000 rpm at 4°C.  Concentrated proteins were 1053 
filtered with 0.22 µm low protein binding Durapore® (PVDF) membrane (Merck Millipore 1054 
Ltd.).  Protein concentrations were quantified by Pierce™ bicinchoninic acid (BCA) assay 1055 
(Pierce Biotechnology) using bovine serum albumin (BSA) as a standard.  1056 
 1057 
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4.2.5 SPR: Binding affinity of bryostatin compounds to C1b domains  1058 
4.2.5.1 Chip, Buffers, Protocol 1059 
Binding affinities of constructs pKBbn2512, pKBbp311, pKBrt2511, and 1060 
pKBbn2512_H12T with bryostatin-1 and phorbol 12-myristate 13-acetate (PMA) were 1061 
quantified using surface plasmon resonance (SPR).  SPR experiments were performed with 1062 
pKBbn2512, pKBbp311, pKBrt2511, and pKBbn2512h>t affixed to Series S Sensor Chip CM5 1063 
(GE Healthcare) via the amine coupling.  The NTA sensor chip consists of a gold metal film on 1064 
one side, and the other side is a carboxymethylated dextran that irreversibly immobilize 1065 
molecules via -NH2, -SH, -CHO, -OH, or -COOH groups.  The gold metal film is exposed to a 1066 
polarized light source causing the excitation of electrons on the gold metal surface, resulting in 1067 
surface plasmons.  The PKC δ C1b domains, ligands, are tethered to the chip and will be exposed 1068 
to the analytes of bryostatin-1 and PMA.  Binding associations (ka) and disassociations (kd) of 1069 
ligands to analyte are provided in a sensorgram data consisting of data points of RU plotted 1070 
versus time (seconds).  The affinity constant KD is calculated by the ratio of rate constants ka and 1071 
kd (KD = kd / ka).  The Kd was measured at multiple analyte concentrations ranging between 0.1 1072 
and 10 times the Kd of the interaction. Bryostatin-1 was resuspended in 0.1% DMSO and diluted 1073 
to a concentration of 55 μM. PMA was resuspended in 100% DMSO and diluted to a 1074 
concentration of 50 μM in 0.1% DMSO. 1075 
Surface plasmon resonance was performed on a Biacore T-200 (GE Healthcare, Uppsala, 1076 
Sweden) instrument using two Series S Sensor Chip CM5 (Lot # 10252793 and Lot # 1009028, 1077 
GE Healthcare, Uppsala, Sweden).  The experimental running buffer consisted of 0.01 M 1078 
HEPES pH 7.4, 0.15 M NaCl, 0.005% Tween 20, and 0.1% Dimethyl sulfoxide (DMSO).  1079 
Approximately 30 µg / mL of pKBbn2512, pKBbp311, pKBrt2511, and pKBbn2512_H12T was 1080 
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bound to the CM5 chips via amine coupling 20 μM N-hydroxysuccinimide (NHS) / 5 μM 1-1081 
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (Amine Coupling Kit, GE Healthcare, 1082 
Uppsala, Sweden) for 7 min at flow rate of 5 μl/min and excess cross linkers were quenched 1083 
by injection of 1 M ethanolamine for 10 min.   1084 
Single cycle kinetics were measured at 10 hertz (Hz) with a 30 µL/min flow rate for a 30 1085 
second association time and a 30 second dissociation time at 25°C. Bryostatin-1 and PMA were 1086 
diluted in HBS-P + 0.1% DMSO to achieve experimental analyte concentrations of 0 µM, 0.625 1087 
µM, 1.25 µM, 2.5µM, 5 µM, 10 µM, 12.5µM, and 15 µM.  Due to bryostatin-1’s sensitivity to 1088 
UV light, fresh analyte concentrations were made for each experimental SPR run.  Response 1089 
units and time were evaluated using Biacore T200 Software v3.1 with parameters of 4 seconds 1090 
before injection stop and 5 seconds after with a steady state curve fit.  Channel one of each CM5 1091 
chip was used as a reference blank to subtract background to achieve a baseline for accurate KD 1092 
calculations.  DMSO correction curves were utilized to extrapolate the background caused by the 1093 
DMSO non-specific binding.  For each experiment, a new correction curve concentrations were 1094 
prepared by diluting 100% DMSO to 2% using HBS-P + 0.1 % DMSO then serially diluted to 1095 
100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.125 nM concentrations.  1096 
4.3 Results  1097 
4.3.1 Identification of PKC C1b δ domains  1098 
PCR amplification of B. turrita, B. turbinata, B. simplex, B. pacifica, and B. stolonifera 1099 
using the primers proved challenging.  Across the Bugula species and PKC isoforms primer sets 1100 
analyzed, only B. pacifica PKC δ C1b domain amplified with a C1b domain sequence that 1101 
differed from that of B. neritina.  Rattus norvegicus PKC δ C1b domain was also amplified 1102 
successfully.  1103 
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 1104 
 1105 
4.3.2 Construction and Purification of PKC δ C1b domains 1106 
B. neritina, B. neritina H12T, B. pacifica, and R. norvegicus PKC δ C1b domains were 1107 
all successfully ligated into pET28b vectors.  Protein overexpression in BL21 cells and protein 1108 
Figure 4.1: Alignment of PKC δ C1b Domains Identified 
B. neritina 
B. neritina H12T 
B. pacifica 
R. norvegicus 
pKBbp311 pKBrt2511 pKBbn2512_H12T pKBbn2512 
Figure 4.2:SDS-Page of Purified PKC δ C1b Domain 
Overexpressed purified proteins of B. neritina PKC δ C1b domain (pKBbn2512, ~10.7kDa), B. pacifica 
PKC δ C1b domain (pKBbp311, ~10.7 kDa), R. norvegicus (pKBrt2511, ~10.7 kDa), and B. neritina H12T 
(pKB2512_H12T, ~10.7 kDa) with NEB (10-250 kDa) protein ladder 
 ~ 10 kDa 
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purification procedures were also successful producing adequate protein concentrations for 1109 
future SPR experiments (Figure 4.2).  Protein concentration for pKB114 was 629.3 µg/mL while 1110 
pKBbn2512_H12T was 529.1 µg/mL.  pKBrt2511 had the highest concentration at 1943.4 1111 
µg/mL and pKBbp311 was lowest at 242.4 µg/mL. 1112 
 1113 
4.3.3 Binding Affinities for PKC δ C1b Domains to Bryostatin-1 1114 
Surface density of protein attachment to the CM5 Chip (Lot # 1009028) for pKBbn2512 1115 
was 1512 RU while pKBbp311 was 1470 RU and CM5 Chip (Lot # 10252793) had 1046.4 RU 1116 
of pKBbn2512_H12T immobilized with 1764.2 RU of pKBrt2511.  Data for the KD values 1117 
obtained during the SPR experiments with bryostatin-1 as the analyte were plotted response 1118 
(response units) versus concentration (M) (Figure 4.2 -4.5).  KD raw data of binding affinities for 1119 
each experiment were recorded (Table 4.3).  KD values of PKC δ C1b domains from B. pacifica 1120 
(pKBbp311), R. norvegicus (pKBrt2511), and B. neritina H12T were normalized to B. neritina 1121 
(pKBbn2512) KD values.  Normalized binding affinities values for B. pacifica ranged from 0.02 1122 
to 4.21 with an average of 1.30 and standard deviation of these values was 1.51.  R. norvegicus 1123 
normalized values ranged from 0.11 to 6.56 with an average of 2.81 and standard deviation of 1124 
2.66.  B. neritina His12 to Thr12 substitution normalized KD values ranged from 0.44 to 4.76 1125 
with an average of 1.75 and a standard deviation of 1.56 (Table 4.4).  1126 
 1127 
 1128 
 1129 
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 1130 
 1131 
 1132 
 1133 
 1134 
 1135 
 1136 
pKBbn2512 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of bryostatin 
plotted with response units (RU) versus concentration in molarity (M). KD value of 5.917E-6. 
Figure 4.3: SPR Experiment of B. neritina PKC δ C1b domain (pKBbn2512) versus Bryostatin-1 
 
pKBbp311 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of bryostatin 
plotted with response units (RU) versus concentration in molarity (M). KD value of 3.77E-6. 
Figure 4.4: SPR Experiment of B. pacifica PKC δ C1b domain (pKBbp311) versus Bryostatin-1 
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 1137 
 1138 
 1139 
 1140 
 1141 
 1142 
 1143 
 1144 
pKBrt2511 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of bryostatin 
plotted with response units (RU) versus concentration in molarity (M). KD value of 4.161E-6. 
Figure 4.5: Experiment of R. norvegicus PKC δ C1b domain (pKBrt2511) versus Bryostatin-1 
pKBbn2512_H12Texposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of 
bryostatin plotted with response units (RU) versus concentration in molarity (M). KD value of 3.543E-6. 
Figure 4.6: SPR Experiment of B. neritina PKC δ C1b domain H12T (pKBrt2512_H12T) versus Bryostatin-1 
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Table 4.3: Binding Affinity of Bryostatin-1 to PKC δ C1b Constructs 1145 
PKC δ C1b Construct vs Bryostatin-1 KD Value 
pKBbn2512 pKBbp311 pKBrt2511 pKBbn2512H>T 
2.02E-06 1.38E-06 2.54E-06 3.54E-06 
5.92E-06 1.01E-07 3.88E-06 5.11E-06 
1.52E-06 1.85E-06 8.30E-06 1.43E-06 
6.34E-07 2.67E-06 4.16E-06 3.02E-06 
1.09E-05 3.77E-06 1.21E-06 4.77E-06 
 1146 
 1147 
 1148 
 1149 
                   Table 4.4: Normalized Binding Affinities of Bryostatin-1and PKC C1b Domains 1150 
Binding Affinities Normalized to B. neritina 
BP311 RT2511 BN2512:HT 
0.68 1.26 1.76 
0.02 0.66 0.86 
1.22 5.47 0.94 
4.21 6.56 4.76 
0.35 0.11 0.44 
Average Normalized 
1.30 2.81 1.75 
Standard Deviation 
1.51 2.66 1.56 
 1151 
 1152 
 1153 
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4.3.4 Binding Affinities for PKC δ C1b Domains to PMA 1154 
Response units (RU) of pKBbn2512, pKBbp311, pKBrt2511, and pKBbn2512_H12T 1155 
and PMA interactions were plotted response against analyte concentrations (M) to obtain binding 1156 
affinities, KD values. (Figure 4.6 - 4.9).  KD raw data of binding affinities for each experiment 1157 
were recorded (Table 4.5).  KD values of PKC δ C1b domain binding affinity from B. pacifica 1158 
(pKBbp311), R. norvegicus (pKBrt2511), and B. neritina H12T to PMA were normalized to B. 1159 
neritina (pKBbn2512) PMA KD values.  Normalized binding affinities values for B. pacifica 1160 
ranged from 0.02 to 3.38 with an average of 1.01 and standard deviation of these values was 1161 
1.25.  R. norvegicus normalized values ranged from 0.61 to 5.02 with an average of 2.25 and 1162 
standard deviation of 1.54.  B. neritina His12 to Thr12 substitution normalized KD values ranged 1163 
from 0.10 to 1.12 with an average of 0.49 and a standard deviation of 0.37 (Table 4.4).  1164 
 1165 
 1166 
 1167 
 1168 
 1169 
 1170 
 1171 
 1172 
 1173 
 1174 
 1175 
 1176 
pKBbn2512 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of PMA plotted 
with response units (RU) versus concentration in molarity (M). KD value of 1.17E-6. 
Figure 4.7: SPR Experiment of B. neritina PKC δ C1b domain (pKBbn2512) versus PMA 
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 1177 
 1178 
 1179 
 1180 
 1181 
 1182 
 1183 
pKBbp311 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of PMA plotted 
with response units (RU) versus concentration in molarity (M). KD value of 1.78E-6. 
Figure 4.8: SPR Experiment of B pacifica PKC δ C1b domain (pKBbp311) versus PMA 
pKBrt2511 exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of PMA plotted 
with response units (RU) versus concentration in molarity (M). KD value of 1.78E-6. 
Figure 4.9: SPR Experiment of R. norvegicus PKC δ C1b domain (pKBrt2511) versus PMA 
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 1184 
 1185 
 1186 
 1187 
               Table 4.5: Binding Affinity of PMA to PKC δ C1b Constructs 1188 
 1189 
 1190 
 1191 
 1192 
 1193 
PKC δ C1b Construct vs PMA KD Value  
pKBbn2512 pKBbp311 pKBrt2511 pKBbn2512_H12T 
1.17E-05 2.39E-08 5.01E-06 9.14E-07 
6.88E-06 1.78E-06 7.05E-06 5.88E-07 
1.84E-06 2.10E-06 4.05E-06 8.91E-07 
2.81E-06 9.49E-06 6.66E-06 3.15E-06 
9.98E-07 2.62E-06 7.14E-06 1.19E-06 
pKBbn2512_H12T exposed to 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 12.5 µM, and 15 µM of PMA 
plotted with response units (RU) versus concentration in molarity (M). KD value of 3.14E-6. 
Figure 4.10: SPR Experiment of B. neritina PKC δ C1b domain H12T (pKBrt2512_H12T) versus PMA 
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Table 4.6:Binding Affinities of PMA Experiments Normalized to B. neritina 1195 
PMA Binding Affinities Normalized to B. neritina 
BP311 RT2511 BN2512:HT 
0.02 5.02 0.59 
0.26 1.02 0.13 
1.14 2.20 0.48 
3.38 2.38 1.12 
0.22 0.61 0.10 
Average Normalized 
1.01 2.25 0.49 
Standard Deviation 
1.25 1.54 0.37 
 1196 
 1197 
4.4 Discussion  1198 
A general rule of binding affinity is that the lower the KD value the higher the affinity for 1199 
the ligand.  Dissociation constant (KD) values represent the point where the ligand, PKC C1b 1200 
domains, and analyte, bryostatin-1 or PMA, molecules are bound to ligand at equilibrium (half 1201 
bound and half unbound).  Binding affinities are values taken at a specific time duration the 1202 
experiments. Saturation levels of ligand-analyte binding will vary according to the strength at 1203 
which the interaction occurs.  Not only does the time at which the changes in light occur effect 1204 
affinities, pH, temperature, and buffer can vary the results of any experiment (Kuriyan, 2008). 1205 
Bryostatin-1 and PMA are small molecules which are soluble in DMSO.  DMSO concentrations 1206 
were kept as low as possible at 0.1% and were consistent throughout samples and buffers; 1207 
however, DMSO can alter the affinity due to non-specific binding to the chip surface.  In order to 1208 
counteract this issue, correction curves were used in each experiment to subtract the background 1209 
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caused by the DMSO.  Surface density of the attached protein to the chip channel can also play 1210 
role in the variation of light refraction and subsequent affinity readings.  Immobilized protein 1211 
concentrations were kept uniform at 30 ng/µL for surface density consistency since KD is a 1212 
measure of protein molecules that are bound to the analyte. 1213 
Binding affinities of the PKC δ c1b domains to bryostatin-1 and PMA showed variation 1214 
across the constructs.  On average, B. pacifica C1b domain had a binding affinity to bryostatin-1 1215 
that was very close to of B. neritina in both bryostatin-1 and PMA experiments.  R. novergicus 1216 
had noteworthy differences in KD values from B. neritina with normalized averages of 2.81 for 1217 
bryostatin-1 and 2.25 with PMA.  B. neritina H12T had average normalized binding of 1.75, 1218 
while higher than B. pacifica, showed no major difference from that of B. neritina bryostatins 1219 
under the conditions of this experiment.  The average binding affinity of PMA to 1220 
pKBbn2512_H12T had the smallest margin of difference from pKBbn2512, but it still was not as 1221 
notable of a difference to that of B. pacifica.  The amino acid substitution of the threonine for the 1222 
histidine at position 12 in B. neritina did make the construct more similar to B. pacifica in 1223 
sequence; however, it did not majorly alter the binding affinity in bryostatin-1 or PMA 1224 
experiments to resemble B. pacifica C1b domain more than pKBbn2512 under these conditions.  1225 
Due to this data, it is possible that the histidine residue at position 12 is not involved in the 1226 
ability of bryostatin-1 to activate PKCs.  While R. norvegicus and B. pacifica have never been 1227 
exposed to the bryostatin compound naturally and only R. norvegicus had a meaning change in to 1228 
the bryostatin-1 than that of B. neritina.   1229 
4.5 Conclusion 1230 
The previous exposure of B. neritina to bryostatin compounds via symbiont could have 1231 
caused an evolutionary change in the host PKCs.  Notable differences in ligand-B. neritina C1b 1232 
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binding affinity of versus R. norvegicus that has not had the same exposure could suggest a 1233 
certain amount of coevolution.  No remarkable changes in the binding affinity of 1234 
pKBbn251_H12T to bryostatin-1 versus B. neritina could mean that the substitution at position 1235 
12 to a threonine might not be involved in bryostatin affinity to PKCs. Continued work on amino 1236 
acid substitutions in B. neritina could provide more evidence about which amino acids are 1237 
involved in PKC activation.  Also, more Bugula spp. PKC C1b domains should be identified 1238 
across the conventional and novel isoforms, and cloned with protein expression to further test the 1239 
effects that bryostatin-1 can have on C1b domains.  Binding affinity differences between the 1240 
Bugula spp. with and without natural bryostatins could lead to a better understanding of where 1241 
and how the bryostatin-1 interacts with C1b domains for PKC activations.  1242 
  1243 
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5 CONCLUSIONS 1244 
 1245 
5.1 Summary 1246 
Symbiotic relationships can be classified in many ways, from mutualistic to parasitic. In 1247 
many cases, the symbiont biosynthesizes natural products that can be utilized by the host. For B. 1248 
neritina, the symbiont E. sertula synthesizes bryostatins using an unusual trans-AT PKS system. 1249 
The mechanism by which the trans-AT recognizes the correct enzymatic domain for formation 1250 
of the bryostatin polyketide is not fully characterized.  The research of protein-protein 1251 
interactions between trans-AT and the KS-AT interdomain regions has determined the potential 1252 
PKS KS-AT region of the module location as where trans-AT interaction occurs.   1253 
The bioactive bryostatins may also play a role in in the host-symbiont interaction.  1254 
Understanding how the host adapts to symbiont-produced natural products will illustrate another 1255 
mechanism of host-symbiont co-evolution.  Bryostatins are useful in deterring the predation of B. 1256 
neritina larvae, but are potent PKC activators via C1b domain binding.  In this study, I 1257 
determined binding affinities of bryostatin-1 and PMA compounds to PKC C1b domains from B. 1258 
neritina and other Bugula spp. to establish the relative interaction with each Bugula spp. to 1259 
bryostatins.  These data can advance knowledge of how the Bugula host has potentially adapted 1260 
to the symbiont-produced bryostatins over time. 1261 
 1262 
  1263 
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